HU000035770T2

(19) **HU**

(11) Lajstromszám: **E 035 770**

(13) **T2**

MAGYARORSZÁG
Szellemi Tulajdon Nemzeti Hivatala

EURÓPAI SZABADALOM
SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 09 794932**
(22) A bejelentés napja: **2009. 06. 16.**

(96) Az európai bejelentés bejelentési száma:
EP 20090794932
(97) Az európai bejelentés közzétételi adatai:
EP 2285350 A2 **2010. 01. 14.**
(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2285350 B1 **2017. 11. 15.**

(51) Int. Cl.: ***A61K 9/16*** *(2006.01)*
A61K 47/34 *(2006.01)*
A61P 35/00 *(2006.01)*
A61K 9/51 *(2006.01)*

(86) A nemzetközi (PCT) bejelentési szám:
PCT/US 09/047554
(87) A nemzetközi közzétételi szám:
WO 10005740

(30) Elsőbbségi adatok:
61712 **2008. 06. 16.** **US**

(72) Feltaláló(k):
ALI, Mir, M., Woburn MA 01801 (US)
HRKACH, Jeff, Lexington MA 02421 (US)
ZALE, Stephen, E., Hopkinton MA 01748 (US)
ALVAREZ DE CIENFUEGOS, Luis, Granada 18009 (ES)

(73) Jogosult(ak):
Pfizer Inc, New York, NY 10017 (US)

(74) Képviselő:
Danubia Szabadalmi és Jogi Iroda Kft., Budapest

(54) **Eljárás terápiás nanorészecskék készítésében való alkalmazásra szánt, targetáló anyaggal funkcionalizált diblokk kopolimerek előállítására**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 2 285 350 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
15.11.2017 Bulletin 2017/46

(21) Application number: **09794932.5**

(22) Date of filing: **16.06.2009**

(51) Int Cl.:
A61K 9/16 *(2006.01)* ***A61K 47/34*** *(2017.01)*
A61P 35/00 *(2006.01)* ***A61K 9/51*** *(2006.01)*

(86) International application number:
PCT/US2009/047554

(87) International publication number:
WO 2010/005740 (14.01.2010 Gazette 2010/02)

(54) **METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC NANOPARTICLES**

VERFAHREN ZUR HERSTELLUNG VON MIT TARGETING-MITTELN FUNKTIONALISIERTEN DIBLOCK-COPOLYMEREN ZUR VERWENDUNG BEI DER HERSTELLUNG THERAPEUTISCHER NANOPARTIKEL

PROCÉDÉS POUR LA PRÉPARATION DE COPOLYMÈRES DIBLOCS FONCTIONNALISÉS AVEC UN AGENT DE CIBLAGE DESTINÉS À ÊTRE UTILISÉS DANS LA FABRICATION DE NANOPARTICULES THÉRAPEUTIQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA RS

(30) Priority: **16.06.2008 US 61712**

(43) Date of publication of application:
23.02.2011 Bulletin 2011/08

(73) Proprietor: **Pfizer Inc.**
New York, NY 10017 (US)

(72) Inventors:
- **ALI, Mir, M.**
  Woburn
  MA 01801 (US)
- **HRKACH, Jeff**
  Lexington
  MA 02421 (US)
- **ZALE, Stephen, E.**
  Hopkinton
  MA 01748 (US)
- **ALVAREZ DE CIENFUEGOS, Luis**
  Granada 18009 (ES)

(74) Representative: **Pfizer**
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 (FR)

(56) References cited:
WO-A1-2004/089345 **WO-A2-2004/096998**
WO-A2-2007/133807 **US-A1- 2002 197 261**
US-A1- 2005 042 298 **US-A1- 2005 266 067**

- **FAROKHZAD OMID C ET AL: "Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 103, no. 16, 1 April 2006 (2006-04-01), pages 6315-6320, XP002495677, ISSN: 0027-8424, DOI: 10.1073/PNAS.0601755103**
- **GARINOT M ET AL: "PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 120, no. 3, 31 July 2007 (2007-07-31) , pages 195-204, XP002694338, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2007.04.021 [retrieved on 2007-05-22]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Printed by Jouve, 75001 PARIS (FR)

(Cont. next page)

- F. GU ET AL: "From the Cover: Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 105, no. 7, 19 February 2008 (2008-02-19), pages 2586-2591, XP055001312, ISSN: 0027-8424, DOI: 10.1073/pnas.0711714105

Description

BACKGROUND OF THE INVENTION

[0001] The delivery of a drug to a patient with controlled-release of the active ingredient has been an active area of research for decades and has been fueled by the many recent developments in polymer science. In addition, controlled release polymer systems can be designed to provide a drug level in the optimum range over a longer period of time than other drug delivery methods, thus increasing the efficacy of the drug and minimizing problems with patient compliance.

[0002] Biodegradable particles have been developed as sustained release vehicles used in the administration of small molecule drugs, proteins and peptide drugs, and nucleic acids. The drugs are typically encapsulated in a polymer matrix which is biodegradable and biocompatible. As the polymer is degraded and/or as the drug diffuses out of the polymer, the drug is released into the body.

[0003] Targeting controlled release polymer systems (*e.g.,* targeted to a particular tissue or cell type or targeted to a specific diseased tissue but not normal tissue) is desirable because it reduces the amount of a drug present in tissues of the body that are not targeted. This is particularly important when treating a condition such as cancer where it is desirable that a cytotoxic dose of the drug is delivered to target cells without killing the surrounding tissue. Accordingly, a need exists to develop delivery systems which can deliver therapeutic levels of drug to treat diseases such as cancer, while also reducing patient side effects.

BRIEF SUMMARY OF THE INVENTION

[0004] This application provides methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers in accordance with the claims. These diblock copolymers comprise a functional PEG polymer block bearing a targeting agent on one of its termini and a second biocompatible and biodegradable hydrophobic polymer block (e.g. a poly(ester)). The poly(ethylene glycol) is hetero-bifunctional with a targeting agent (TA) covalently bound to its α terminus and a polymerization initiating functional group (e.g., a hydroxyl group) present on its ω terminus. Alternatively, the poly(ethylene glycol) is functionalized with a TA on its α terminus and a functional group capable of covalent attachment to a poly(ester) that in turn is functionalized with a reactive end group. Examples include an amino-terminated PEG and a carboxylic acid terminated poly(ester) or an azide terminated PEG and an alkyne terminated poly(ester). Nanoparticles produced according to the disclosed methods and their use in the treatment of various diseases and disorders is also provided.

BRIEF DESCRIPTION OF THE FIGURES

[0005]

Figures 1A-C: Proton NMR spectra of HO-PEG-lys-urea-glu(protected), lot numbers 11-189-1 and 11-176-1. Figure 1A - HO-PEG-lys-urea-glu(protected) Lot# 11-176-1. 1H NMR spectrum expansion #1 used for lys-urea-glu(protected) content calculation (%lys-urea-glu(protected) end functionalization = [Int. δ1.95-2.1]*2/[Int. δ2.15-2.3] * 100% = [2 * 10847/25777]*100 = 84%). Figure 1B - HO-PEG-lys-urea-glu(protected) Lot# 11-176-1; 1H NMR spectrum expansion #2. Figure 1C - HO-PEG-lys-urea-glu(protected) Lot# 11-176-1; 1H NMR spectrum expansion #3.

Figures 2A-B: Size Exclusion Chromatograms (SEC) of HO-PEG-lys-urea-glu(protected), lot numbers 11-189-1 (Figure 2B) and 11-176-1 (Figure 2A).

SEC conditions:

Detector: Refractive Index detection (RI); RI Detector temperature = 35 °C
Columns: Water Styragel (HR1, 100 - 5000 Da; HR3, 500 - 30000 Da; HR4, 5000 - 600,000 Da in series).
Column Temperature = 30 °C;
Mobile phase: Chloroform; Flow rate: 1 mL/min
Sample concentration = 10 mg/mL, Injection volume = 50 uL (11-176-1) and 100 uL (11-189-1 coded 44-44-6 in chromatogram legends below);
Number and Weight Average Molecular Weight (M_n and M_w) and Polydispersity (M_w/M_n) were obtained relative to narrow disperse Poly(ethylene glycol) Standards (Polymer Standards Service USA, Warwick, Rhode Island). A fourth order polynomial fit (R^2 = 0.99957; Standard Error = 0.02) was used for calibration. 11-176-1 (Fig. 2A) and 11-189-1 (Fig. 2B) SEC Chromatograms

Figures 3A-F: Proton NMR spectra of PLA-PEG-lys-urea-glu(protected), lot numbers 11-187-1, 11-188-1 and 11-198-1.

NMR Instrument: Bruker 400MHz
NMR Experiment parameters:

Solvent: $CDCl_3$; Pulse Width: 7.5 usec; Pulse Delay: 5 sec; Number of scans: 128

Figure 3A - PLA-PEG-lys-urea-glu(protected), Lot # 11-187-1; 1H NMR Spectrum Expansion #1 showing lactide methine and allyl end group peak used in the determination the determination of the absolute number average molar mass (Mn) of PLA-PEG-lys-urea-glu(protected). Method for determination of absolute number average molar mass (M_n) of PLA-PEG-lys-urea-glu(protected): M_n(PLA-PEG-lys-urea-glu(protected) = M_n(PEG-lys-urea-glu(protected) + (Molar mass of lactide repeat unit*((Int. δ5.1ppm - 5.3ppm)*3)/(Int.δ5.85ppm - 5.95ppm) = 5000 + ((72*10,000)*3)/143) = 20,105 Da. Figure 3B - PLA-PEG-lys-urea-glu(protected), Lot# 11-187-1; 1H NMR Spectrum Expansion #2 showing PEG peak and lactide methyl peaks of PLA-PEG-lys-urea-glu(protected). Figure 3C - PLA-PEG-lys-urea-glu(protected), Lot# 11-188-1; 1H NMR Spectrum Expansion #1 showing lactide methine and allyl end group peak used in the determination the determination of the absolute number average molar mass (Mn) of PLA-PEG-lys-urea-glu(protected). Method for determination of absolute number average molar mass (M_n) of PLA-PEG-lys-urea-glu(protected): M_n(PLA-PEG-lys-urea-glu(protected) = M_n(PEG-lys-urea-glu(protected) + (Molar mass of lactide repeat unit*((Int. δ5.1ppm - 5.3ppm)*3)/(Int.δ5.85ppm - 5.95ppm) = 5000 + ((72*10,000)*3)/137) = 20,766 Da. Figure 3D - PLA-PEG-lys-urea-glu(protected), Lot# 11-188-1; 1H NMR Spectrum Expansion #2 showing PEG peak and lactide methyl peaks of PLA-PEG-lys-urea-glu(protected). Figure 3E - PLA-PEG-lys-urea-glu(protected), Lot# 11-198-1; 1H NMR Spectrum Expansion #1 showing lactide methine and allyl end group peak used in the determination the determination of the absolute number average molar mass (Mn) of PLA-PEG-lys-urea-glu(protected). Method for determination of absolute number average molar mass (M_n) of PLA-PEG-lys-urea-glu(protected): M_n(PLA-PEG-lys-urea-glu(protected) = M_n(PEG-lys-urea-glu(protected) + (Molar mass of lactide repeat unit*((Int. δ5.1ppm - 5.3ppm)*3)/(Int.δ5.85ppm - 5.95ppm) = 5000 + ((72*10,000)*3)/156) = 18,846 Da. Figure 3F - PLA-PEG-lys-urea-glu(protected), Lot# 11-198-1; 1H NMR Spectrum Expansion #2 showing PEG peak and lactide methyl peaks of PLA-PEG-lys-urea-glu(protected).

Figure 4: Size Exclusion Chromatograms (SEC) of HO-PEG-lys-urea-glu(protected), lot numbers 11-189-1 (labeled 44-44-6 for SEC analysis) and 11-176-1.

Size Exclusion Chromatographic conditions:

Detector: Refractive Index detection (RI); RI Detector temperature = 35 °C
Columns: Water Styragel (HR1, 100 - 5000 Da; HR3, 500 - 30000 Da; HR4, 5000 - 600,000 Da in series). Column Temperature = 30 °C; Mobile phase: Chloroform; Flow rate: 1 mL/min
Sample concentration = 10 mg/mL, Injection volume = 20 uL;
Number and Weight Average Molecular Weight (M_n and M_w) and polydispersity (M_w/M_n) were obtained relative to narrow disperse Poly(styrene) Standards (Shodex Standards, Kawasaki, Japan). A fourth order polynomial fit (R^2 = 0.999927; Standard Error = 0.008) was used for calibration.

Figures 5A-E: Efficiency of deprotection and estimate of Molar mass of crude PLA-PEG-lys-urea-glu (prior to palladium removal) by 1H NMR Spectroscopy.
NMR Instrument: Bruker 400MHz
NMR Experiment parameters:

Solvent: $CDCl_3$; Pulse Width: 7.5 usec; Pulse Delay: 5 sec; Number of scans: 128

Figure 5A - Crude PLA-PEG-lys-urea-glu Lot# 11-190-1; 1H NMR Spectrum Expansion #1 showing: a) lactide methine peak, b) peaks of aromatic protons of tetrakis(triphenyl-phosphine)palladium (0), and c) absence of residual allyl peaks (δ 5.85 - 5.95) indicating quantitative removal of protecting groups. Figure 5B - Crude PLA-PEG-lys-urea-glu Lot# 11-190-1; 1H NMR Spectrum Expansion #2 showing the PEG and lactide methyl peaks. Figure 5C - Crude PLA-PEG-lys-urea-glu Lot# 11-191-1; 1H NMR Spectrum Expansion #1 showing: a) lactide methine peak, b) peaks of aromatic protons of tetrakis(triphenyl-phosphine)palladium (0), and c) < 3% (relative to the PLA-PEG-lys-urea-glu(protected) precursor) residual allyl peaks (δ 5.85 - 5.95) indicating > 96% removal of protecting groups. Figure 5D - Crude PLA-PEG-lys-urea-glu Lot# 11-191-1; 1H NMR Spectrum Expansion #2 showing PEG and lactide methyl peaks. Figure 5E - Crude PLA-PEG-lys-urea-glu Lot# 11-199-1; 1H NMR Spectrum Expansion #1 showing: a) lactide methine peak, b) absence of residual allyl peaks (δ 5.85 - 5.95) indicating quantitative removal of protecting groups. Figure 5F - Crude PLA-PEG-lys-urea-glu Lot# 11-199-1; 1H NMR Spectrum Expansion #2 showing PEG and lactide methyl peaks.

Figures 6A-B: Molar Mass and PEG fraction of purified PLA-PEG-lys-urea-glu by 1H NMR Spectroscopy.
NMR Instrument: Bruker 400MHz
NMR Experiment parameters:

Solvent: $CDCl_3$; Pulse Width: 7.5 usec; Pulse Delay: 5 sec; Number of scans: 128

Figure 6A - PLA-PEG-lys-urea-glu Lot# 44-49-1; IH NMR Spectrum Expansion #1 showing: a) lactide methine peak, b) absence of residual allyl peaks (δ 5.85 - 5.95) indicating quantitative removal of protecting groups. Figure 6B - Purified PLA-PEG-lys-urea-glu Lot# 44-49-1; IH NMR Spectrum Expansion #2 showing PEG and lactide methyl peaks.

Figure 7: Molecular weight of PLA-PEG-lys-urea-glu and the protected precursor PLA-PEG-lys-urea-glu(protected) by Inherent Viscosity measurements.

Figure 8: Palladium Content in crude (prior to palladium removal) PLA-PEG-lys-urea-glu lot number 44-48-1 (sample code 11-204-1) and purified (after palladium removal) PLA-PEG-lys-urea-glu lot number 44-49-1 (sample code 11-204-2) determined by ICP Spectrometry.

DETAILED DISCLOSURE OF THE INVENTION

[0006] This application provides methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers in accordance with the claims. These diblock copolymers comprise a bio-active poly(ethylene glycol) block and a second biocompatible and biodegradable hydrophobic polymer block (e.g. a poly(ester)). The poly(ethylene glycol) is hetero-bifunctional with a targeting moiety (agent) covalently bound to its α terminus and a polymerization initiating functional group (e.g., a hydroxyl group) present on its ω terminus.

[0007] The subject application also provides for the use of derivatives of targeting agents (TA' s) (e.g., analogs where functional groups, such as carboxylic acids or other functional groups, are protected) in the synthesis of the poly(ethylene glycol) polymer to which TA's are attached that improve its solubility and avoid potential side reactions. After a protected targeting agent (PRO-TA) is coupled to the PEG polymer at the α terminus, the functionalized PEG (HO-PEG-TA-PRO) is utilized as a macroinitiator to synthesize a poly(ester) block. For example, HO-PEG-TA-PRO is added to a mixture of cyclic lactone monomers such as lactide, glycolide or caprolactone and the mixture is heated to melt conditions. A polymerization catalyst, such as tin (II) 2-ethylhexanoate is then added to the monomer/initiator melt. The resulting polymer is purified from un-reacted monomer and polymerization catalyst by precipitation into a non-solvent mixture such as ether/hexane (70/30) and recovered by decantation followed by vacuum drying. Subsequent deprotection of the protected functional groups can be performed to regain the original chemically active functional group (e.g., a carboxylic acid). This approach enables the desired polymerization reaction to proceed efficiently and avoids side reactions between the polymerization catalyst and the functional groups on the targeting moiety in its native unprotected form. Such side reactions result in the formation of cross-linked insoluble gels rather than the desired linear poly(ester) polymer. In addition, the composition and molecular weight of the poly(ester) can be tuned as desired by controlling the composition of the monomer melt and the molar ratio of the HO-PEG-TA(PRO) to the monomers. Furthermore, the protected targeting moiety is freely soluble in a wide range of organic solvents relative to the un-protected analogues. This enables the coupling of the targeting moiety to poly(ethylene glycol) with a high degree of polymer end group functionalization. Non-limiting examples of protecting groups for various targeting agent functional groups, as disclosed herein, are:

Functional group	Protecting group
Alcohol	Alkyl allyl carbonate, Alloc-OR
Alcohol	Methyl ether
Alcohol	Methyl ether
Alcohol	Methyl ether
Alcohol	Allyl benzylcarbonate, $ROCO_2Bn$
Phenol	Allyl carbonate
Phenol	Methyl ether
Phenol	Benzyloxymethyl ether - BOM
Phenol	Methoxyethoxymethyl Ether - MEM ether
Thiol	S-p-Methoxybenzyl thioether
Thiol	S-Triphenylmethyl thioether (Tr-SR)
Thiol	4-methoxytrityl (Mtt-SR)

(continued)

Functional group	Protecting group
Thiol	S-t-butyl thioether
Thiol	S-[Tricarbonyl[1,2,3,4,5,η]-2,4-dicyclohexadiene-1-yl]-iron(1+) thioether
Amine	N-allylamine
Amine	N-benzylamine
Amine	Allyl carbamate (Alloc-NR_2)
Amine	Benzyl carbamate - benzyloxycarbonyl (CBz)
Amine	p-methoxybenzyl carbamate - Moz
Amine	p-nitrobenzyl carbamate - PNZ
Carboxylic acid	Allyl ester
Carboxylic acid	Propargyl ester
Carboxylic acid	Benzyl ester - RCO_2Bn

[0008] Additionally, this application provides a method for efficient coupling of the un-protected targeting moiety to poly(ethylene glycol) under aqueous conditions. In this approach, the pH of the reaction medium is used to maximize yield of the desired product. Advantages to this aspect of the invention relate to the utilization of the high water solubility of the targeting agent (TA). For example, the acid end group of a α-azide-ω-carboxylic acid poly(ethylene glycol) (N_3-PEG-CO_2H) is first activated by conversion to the succinimide ester N_3-PEG-COSu) by reaction with N-hydroxysuccinimide (NHS) and ethyl dimethylaminopropylcarbodiimide hydrochloride (EDC) or dicyclohexylcarbodiimide (DCC) under anhydrous organic solvent conditions such as in dichloromethane. The activated poly(ethylene glycol) (N_3-PEG-COSu) is subsequently purified from small molecule reagents precipitation into an anhydrous non-solvent such as ether-hexane (70/30). The un-protected form of the amine-functional targeting agent (H_2N-TA) is dissolved in bicarbonate buffer (pH = 9.7) and pH then lowered to 7.4 using aqueous sodium hydroxide. The activated acid (N_3-PEG-COSu) is dissolved in DI water is added dropwise to a large molar excess of the H_2N-TA solution. The succinimide ester of N_3-PEG-COSu is stable at pH = 5.5 - 6, while the amide bond forming reaction with H_2N-TA is efficient under pH = 7.4 conditions. This strategy exposes the N_3-PEG-COSu to pH = 7.4 only when a large excess of amine-functional targeting moiety is also present. Thus, conversion to the desired PEG-targeting agent conjugate (N_3-PEG-TA) while minimizing exposure of the N_3-PEG-COSu to basic conditions, thereby avoiding hydrolysis of the succinimide ester. The N_3-PEG-TA is subsequently coupled to an alkyne terminal poly(ester) using copper catalyst under conventional click chemistry conditions in an organic solvent such as dimethylformamide (DMF) or dimethylsulfoxide (DMSO). Alkyne terminal poly(ester) is prepared by ring opening polymerization of lactide and glycolide monomers using for example propargyl alcohol as polymerization initiator and tin (II) 2-ethyl hexanoate as polymerization catalyst.

[0009] As an example, a targeting moiety/agent may target or cause the particle to become localized at specific locations within a subject and the bioactive agent/therapeutic agent is thus delivered to a target site. In one embodiment, a drug or therapeutic agent can be released in a controlled release manner from the particle and allowed to interact locally with the particular targeted site (e.g., a tumor). The term "controlled release" (and variations of that phrase (*e.g.*, in the context of "controlled-release system")) is generally meant to encompass release of a therapeutic agent (*e.g.,* a drug) at a selected site in a controllable rate, interval, and/or amount. "Controlled release" encompasses, but is not necessarily limited to, substantially continuous delivery, patterned delivery (*e.g.,* intermittent delivery over a period of time that is interrupted by regular or irregular time intervals) or delivery of a bolus of a selected therapeutic agent (or various combinations thereof) as a predetermined, discrete amount over a relatively short period of time (*e.g.,* a few seconds or minutes).

[0010] Examples of second biocompatible and biodegradable hydrophobic polymer blocks that can be used in the manufacture of the claimed nanoparticles can be polyesters. Examplary polyesters suitable for use in the manufacture of the disclosed nanoparticles include copolymers comprising lactic acid and glycolic acid units, such as poly(lactic acid-co-glycolic acid) and poly(lactide-co-glycolide), collectively referred to herein as "PLGA"; and homopolymers comprising glycolic acid units, referred to herein as "PGA," and lactic acid units, such as poly-L-lactic acid, poly-D-lactic acid, poly-D,L-lactic acid, poly-L-lactide, poly-D-lactide, and poly-D,L-lactide, collectively referred to herein as "PLA." In some embodiments, exemplary polyesters include, for example, polyhydroxyacids; PEGylated polymers and copolymers of lactide and glycolide (*e.g.*, PEGylated PLA, PEGylated PGA, PEGylated PLGA, and derivatives thereof. In some em-

bodiments, polyesters include, for example, polyanhydrides, poly(ortho ester) PEGylated poly(ortho ester), poly(caprolactone), PEGylated poly(caprolactone), poly(L-lactide-co-L-lysine), poly(serine ester), poly(4-hydroxy-L-proline ester), poly[a-(4-aminobutyl)-L-glycolic acid], and derivatives thereof.

[0011] Second biocompatible and biodegradable hydrophobic polymer block (e.g., polyesters) utilized in the manufacture of the disclosed nanoparticles can contain functional groups that react with the ω terminus of the poly(ethylene glycol). Non-limiting examples of such functional groups include, and are not limited to, amines, hydroxyl groups, carboxylic acid groups, NHS groups, alkyne groups or azide groups. Groups with which the second biocompatible and biodegradable hydrophobic polymer block functional groups react at the ω terminus of the poly(ethylene glycol) polymer are provided in the following table.

Polyester functional group	Reactive group at the ω terminus of poly(ethylene glycol)
N-hydroxysuccinimide (NHS)	Amine
Amine	Hydroxyl, Carboxylic acid
Hydroxyl	Amine
Carboxylic acid	Amine
Alkyne	Azide

[0012] Targeting agents disclosed herein can contain, or be modified to contain, a functional group that can be reacted with the α terminus of a polymer (*e.g.*, PEG) in order to produce a polymer conjugated to a targeting moiety. The functional groups include any moiety that can be used to create a covalent bond with a polymer (*e.g.*, PEG), such as amino, hydroxy, azide, alkyne and thio. For example, targeting agents can be can be substituted with NH_2, SH or OH, which are either bound directly to the targeting agent or via an additional group, *e.g.,* alkyl or phenyl. In a non-limiting example, aniline, alkyl-NH_2 (*e.g.*, $(CH_2)_{1-6}NH_2$), or alkyl-SH (*e.g.*, $(CH_2)_{1-6}NH_2$) can be used to link the targeting agent to a polymer via the free NH_2 and SH groups to form a covalent bond.

[0013] The conjugation of a functionalized PEG polymer (a PEG polymer comprising one or more targeting agents at its α terminus and reactive functional groups at the ω terminus) and a second biocompatible and biodegradable hydrophobic polymer can be performed according to methods known in the art via functional groups at the ω terminus of a functionalized PEG polymer and reactive groups present in the second biocompatible and biodegradable hydrophobic polymer. For example, EDC-NHS chemistry (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and *N*-hydroxysuccinimide) or a reaction involving a maleimide or a carboxylic acid can be used. The conjugation of a poly(ester) and a poly(ether) to form a poly(ester-ether), can be performed in an organic solvent, such as, but not limited to, dichloromethane, acetonitrile, chloroform, dimethylformamide, tetrahydrofuran, acetone, or the like. Specific reaction conditions can be determined by those of ordinary skill in the art using no more than routine experimentation.

[0014] The conjugation of a functionalized PEG polymer (a PEG polymer comprising one or more targeting agents (TA) at its α terminus and reactive functional groups at the ω terminus) and a second biocompatible and biodegradable hydrophobic polymer can also be performed using chemistries that are orthogonal to the amide bond forming EDC-NHS chemistry. Such methods include "click" chemistry techniques. For example, an alkyne terminated poly(ester) may be reacted with a heterobifunctional poly(ethylene glycol) bearing a TA at its α-terminus and an alkyne reactive azide moiety at its ω-terminus. The conjugation of a poly(ester) and a poly(ether) to form a poly(ester-ether), can be performed in an organic solvent, such as, but not limited to, dichloromethane, acetonitrile, chloroform, dimethylformamide, tetrahydrofuran, acetone, or the like. Conventional "click" chemistry catalysts such as copper sulfate may be employed.

[0015] In another set of embodiments or disclosures, a conjugation reaction may be performed by reacting a polymer that comprises a carboxylic acid functional group (*e.g.,* a poly(ester-ether) compound) with a polymer or other moiety (such as a targeting moiety) comprising an amine. For instance, a targeting moiety, such as a low-molecular weight PSMA ligand, may be reacted with an amine to form an amine-containing moiety, which can then be conjugated to the carboxylic acid of the polymer. Such a reaction may occur as a single-step reaction, *i.e.,* the conjugation is performed without using intermediates such as *N*-hydroxysuccinimide or a maleimide. The conjugation reaction between the amine-containing moiety and the carboxylic acid-terminated polymer (such as a poly(ester-ether) compound) may be achieved, in one set of embodiments, by adding the amine-containing moiety, solubilized in an organic solvent such as (but not limited to) dichloromethane, acetonitrile, chloroform, tetrahydrofuran, acetone, formamide, dimethylformamide, pyridines, dioxane, or dimethysulfoxide, to a solution containing the carboxylic acid-terminated polymer. The carboxylic acid-terminated polymer may be contained within an organic solvent such as, but not limited to, dichloromethane, acetonitrile, chloroform, dimethylformamide, tetrahydrofuran, or acetone. Reaction between the amine-containing moiety and the carboxylic acid-terminated polymer may occur spontaneously, in some cases. Unconjugated reactants may be washed away after such reactions, and the polymer may be precipitated in solvents such as, for instance, ethyl ether, hexane,

methanol, or ethanol.

[0016] Another aspect of the invention is directed to particles that include polymer conjugates such as the ones described above. The particles may have a substantially spherical (*i.e.,* the particles generally appear to be spherical), or non-spherical configuration. For instance, the particles, upon swelling or shrinkage, may adopt a non-spherical configuration. In some cases, the particles may include polymeric blends. For instance, a polymer blend may be formed that includes a first PEG polymer comprising a targeting moiety (*i.e.,* a low-molecular weight PSMA ligand) and a second polymer comprising a biocompatible polymer (e.g., lacking a targeting moiety). By controlling the ratio of the first and second polymers in the final polymer, the concentration and location of targeting moiety in the final polymer may be readily controlled to any suitable degree.

[0017] As discussed above, the polymer may be PLGA in some embodiments. PLGA is a biocompatible and biodegradable co-polymer of lactic acid and glycolic acid, and various forms of PLGA are characterized by the ratio of lactic acid:glycolic acid. Lactic acid can be L-lactic acid, D-lactic acid, or D,L-lactic acid. The degradation rate of PLGA can be adjusted by altering the lactic acid-glycolic acid ratio. In some embodiments, PLGA to be used in accordance with the present invention is characterized by a lactic acid:glycolic acid ratio of approximately 85:15, approximately 75:25, approximately 60:40, approximately 50:50, approximately 40:60, approximately 25:75, or approximately 15:85.

[0018] In particular embodiments, by optimizing the ratio of lactic acid to glycolic acid monomers in the polymer of the nanoparticle (*e.g.,* the PLGA block copolymer or PLGA-PEG block copolymer), nanoparticle parameters such as water uptake, therapeutic agent release (*e.g.,* "controlled release") and polymer degradation kinetics can be optimized. Yet other embodiments provide polymers that may be one or more acrylic polymers. In certain embodiments, acrylic polymers include, for example, copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, methacrylic acid alkylamide copolymer, poly(methyl methacrylate), aminoalkyl methacrylate copolymer, glycidyl methacrylate copolymers, polycyanoacrylates, and combinations comprising one or more of the foregoing polymers.

[0019] In some other embodiments, polymers can be cationic polymers. In general, cationic polymers are able to condense and/or protect negatively charged strands of nucleic acids (*e.g.* DNA, RNA, or derivatives thereof). Amine-containing polymers such as poly(lysine) (Zauner et al., 1998, Adv. Drug Del. Rev., 30:97; and Kabanov et al., 1995, Bioconjugate Chem., 6:7), poly(ethylene imine) (PEI; Boussif et al, 1995, Proc. Natl. Acad. Sci., USA, 1995, 92:7297), and poly(amidoamine) dendrimers (Kukowska-Latallo et al., 1996, Proc. Natl. Acad. Sci., USA, 93:4897; Tang et al., 1996, Bioconjugate Chem., 7:703; and Haensler et al., 1993, Bioconjugate Chem., 4:372) are positively-charged at physiological pH, form ion pairs with nucleic acids, and mediate transfection in a variety of cell lines.


[0020] In yet other embodiments, polymers can be degradable polyesters bearing cationic side chains (Putnam et al., 1999, Macromolecules, 32:3658; Barrera et al., 1993, J. Am. Chem. Soc., 115:11010; Urn et al., 1999,J. Am. Chem. Soc., 121:5633; and Zhou et al, 1990, Macromolecules, 23:3399). Incorporation of hydrophobic comonomers (*e.g.,* lactide, glycolide, caprolactone, or hydrophobic amino acids such as alanine, valine, leucine, isoleucine or phenylalanine) into the polymer backbone to an extent that will impart hydrophobic character to the copolymer enables formation of nanoparticles with a degree of cationic character within the particle core. This in turn enables encapsulation of drugs such as siRNA into the nanoparticle core. Examples of these polyesters include poly(L-lactide-co-L-lysine) (Barrera et al, 1993, J. Am. Chem. Soc., 115:11010), poly(serine ester) (Zhou et al, 1990, Macromolecules, 23:3399), poly(4-hydroxy-L-proline ester) (Putnam et al, 1999, Macromolecules, 32:3658; and Lim et al, 1999, J. Am. Chem. Soc., 121:5633). Poly(4-hydroxy-L-proline ester) was demonstrated to condense plasmid DNA through electrostatic interactions, and to mediate gene transfer (Putnam et al, 1999, Macromolecules, 32:3658; and Lim el al, 1999, J. Am. Chem. Soc., 121:5633). These new polymers are less toxic than poly(lysine) and PEI, and they degrade into non-toxic metabolites.

[0021] In a particular embodiment, the molecular weight of the polymers of the nanoparticles of the invention are optimized for effective treatment of cancer, *e.g.,* prostate cancer. For example, the molecular weight of the polymer influences nanoparticle degradation rate (particularly when the molecular weight of a biodegradable polymer is adjusted), solubility, water uptake, and drug release kinetics (*e.g.* "controlled release"). As a further example, the molecular weight of the polymer can be adjusted such that the nanoparticle biodegrades in the subject being treated within a reasonable period of time (ranging from a few hours to 1-2 weeks, 3-4 weeks, 5-6 weeks, 7-8 weeks, *etc.*). In particular embodiments of a nanoparticle comprising a copolymer of PEG and PLGA, the PEG has a molecular weight of 1,000-20,000 Da (*e.g.,* 5,000-20,000, *e.g.,* 10,000-20,000) and, in some embodiments, 5000 Da, and the PLGA has a molecular weight of 5,000-100,000 Da (*e.g.,* 20,000-70,000, *e.g.,* 20,000-50,000), or in some embodiments, 15,000-30,000 Da.

[0022] The nanoparticles disclosed herein can be used for the treatment of various diseases and disorders within a subject. A subject may be a human or non-human animal. Examples of subjects include, but are not limited to, a mammal such as a dog, a cat, a horse, a donkey, a rabbit, a cow, a pig, a sheep, a goat, a rat, a mouse, a guinea pig, a hamster, a primate, a human or the like.

[0023] The disclosure provides a number of methods of making nanoparticles comprising one or more targeting agent and/or one or more bioactive moiety/therapeutic agent. In various aspects of the invention, a functionalized targeting

agent conjugated diblock copolymer is synthesized by initiating the polymerization of biocompatible and biodegradable hydrophobic polymer (such as poly(ester)) from the ω terminus of the poly(ethylene glycol). Scheme 1 illustrates this process as exemplified by a poly(ethylene glycol) bearing a hydroxyl functional group on its α-terminus and targeting agent (TA) on its ω-terminus. Polymerization of a poly(ester) block from this hydroxyl terminus yields the desired diblock copolymer bearing a TA covalently bound to its PEG terminus.




PEG = poly(ethylene glycol)

TA = Targeting agent

Poly(ester) includes poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide-co-glycolide)

Scheme 1. Method for synthesis of Poly(ester)-block-poly(ethylene glycol) bearing a targeting agent (TA) at its PEG terminus

[0024] According to the invention, a diblock copolymer bearing a targeting agent (TA) on its poly(ethylene glycol) terminus may be prepared by conjugation of a suitably protected form of the targeting agent (TA-PRO) to the poly(ethylene glycol) polymer (yielding HO-PEG-TA(PRO)), and subsequently using this macroinitiator in the ring opening polymerization of a cyclic lactone monomer such as lactide, glycolide or a mixture thereof. Removal of the protecting groups of the targeting agent using standard deprotection methodology provides the desired Poly(ester)-block-PEG-TA (see scheme 2). In a further disclosure, a functional diblock copolymer (Poly(ester)-PEG-TA) may be prepared by the covalent coupling of the targeting PEG-TA to a pre-formed poly(ester). For example, a carboxylic acid terminated poly(lactide-co-glycolide) (Poly(ester)-CO_2H and poly(ethylene glycol) bearing the targeting agent on its α-terminus and an acid reactive amino functional group on its ω-terminus (H_2N-PEG-TA) may be reacted under organic solvent conditions.



PEG = poly(ethylene glycol)

TA = Targeting agent

TA(PRO) = Protected form of the targeting agent


Poly(ester) includes poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide-co-glycolide)

Scheme 2. Method for synthesis of Poly(ester)-block-poly(ethylene glycol) bearing a targeting agent (TA) at its PEG terminus using the protected form of the targeting agent (HO-PEG-TA(PRO)) as a macroiniitiator in the ring opening polymerization of a cyclic lactone monomer

[0025] Targeting agents (TA's) may be comprised of individual natural or non-natural amino acids, or a combination of two or more amino acid residues covalently bound either by a amide or a urea linkage. TA's may also be comprised of nucleic acids. As such, TA's may contain side chain moieties bearing functional groups including carboxylic acids, amines, thiols, alcohols, phenols, guanidine, purines (such as adenine, guanine), pyrimidines (such as cytosine, uracil, thymine). The method of scheme 2 is preferred over the method of scheme 1 when TA's contain functional groups that may either initiate a ring opening polymerization (such as an alcohol, a phenol, an amine, or a thiol) or react with and structurally alter the polymerization catalyst (such as guanidine, 1,5-pentandioic acid moieties as found when a dipeptide

or polypeptide TA has a glutamic acid residue on its C-terminus, or a urea linkage capable of binding to the polymerization catalyst).

[0026] This invention or disclosure also describes methods for the synthesis of covalent conjugates of heterobifunctional poly(ethylene glycol) and targeting agents (TA's). Poly(ethyleneglycol) (PEG) bearing a hydroxyl group at its α-terminus and a reactive functional group on its ω-terminus such as a carboxylic acid, an aldehyde, an azide, an alkyne, a maleimido group, are described herein. Such heterobinfunctional PEG's may be reacted with a TA bearing an amine, a thiol, an alkyne or an azide moiety to yield a covalent conjugate of PEG and TA (HO-PEG-TA). Preferred reactive moieties include amine and carboxylic acid and amine and aldehyde that yield naturally occurring linkages such as amides or secondary amines. Scheme 3 provides chemical synthetic methodologies to enable such covalent conjugation.



PEG = poly(ethylene glycol)

TA = Targeting agent

TA(PRO) = Protected form of the targeting agent

X = carboxylic acid, aldehyde, maleimide, azide or alkyne

Y = amine, thiol, azide or alkyne


Y-TA is used when the targeting agent is free of functional groups capable of undesirable side reactions with X and/or initiating ring opening polymerization or capable of undesirable side reactions with polymerization catalysts

Y-TA(PRO) is used with the targeting agent does not meet the chemical structural requirements outlined above for the use of Y-TA

Conjugation chemistries include acid activation to succinimidyl ester using for example ethyl dimethylaminopropyl carbodiimide (EDC) and/or N-hydroxysuccinimide (NHS) followed by amidation reaction; reductive alkylation involving an aldehyde and amine and subsequent reduction using for example sodium cyanoborohydride; click chemistry involving an azido and alkyne moieties using for example a copper catalyst; thiol-maleimide chemistry to yeild a stable secondary mercaptan.


Scheme 3. Methodologies for synthesis of covalent conjugates of poly(ethylene glycol) and targeting agent (TA) or its protected analogue (TA-PRO)

[0027] This invention also describes methods for the synthesis of HO-PEG-TA(PRO) conjugates under anhydrous organic solvent condition using the preferred amidation reaction of an amine moiety of the TA(PRO) and an acid terminus of PEG. Scheme 4 illustrates the method used for covalent conjugation of HO-PEG-CO_2H to a allyl protected lysine-urea-glutamic acid (lys-urea-glu) targeting agent. Use of the allyl protected analog of the lys-urea-glu targeting agent improves its solubility in organic solvents most suitable (such as dichloromethane) for EDC/NHS acid activation chemistry. Amidation reaction under anhydrous organic solvent conditions enables a high degree of conjugation efficiency and yields over 80% end group functionalization in HO-PEG-lys-urea-glu(allyl protected). Furthermore, the allyl protected lys-urea-glu (TA(PRO)) enables the ring opening polymerization of lactone monomers without undesirable side reaction with the preferred polymerization catalyst (tin (II) 2-ethylhexanoate).




Scheme 4. Synthesis of HO-PEG-lys-urea-glu(allyl protected) conjugate under anhydrous organic solvent conditions using EDC/NHS activation of the acid terminus of PEG followed by amidation by reaction with the amine moiety of TA(PRO)

[0028] This invention also describes methods for the synthesis of HO-PEG-TA(PRO) conjugates under organic solvent condition using reductive alkylation reaction of an amine moiety of the TA(PRO) and an aldehyde terminus of PEG. Scheme 5 illustrates the method used for covalent conjugation of HO-PEG-CHO to allyl protected lysine-urea-glutamic acid (TA(PRO)). Use of the allyl protected analog of the lys-urea-glu targeting moiety improves its solubility in organic solvents (such as dichloromethane, dimethylformamide) suitable for reductive alkylation chemistry. Reductive alkylation under organic solvent conditions enables a high degree of conjugation efficiency and yields over 80% end group functionalization in HO-PEG-lys-urea-glu(allyl protected).




Scheme 5. Synthesis of HO-PEG-lys-urea-glu(allyl protected) conjugate under organic solvent conditions using reductive amination involving the amine moiety of the protected targeting agent (TA(PRO)) and aldehyde terminus of PEG

[0029] This invention also describes the ring opening polymerization of cyclic lactone monomers using the HO-PEG-lys(urea)glu(allyl protected) (HO-PEG-TA(PRO)) conjugate as a macroinitiator and tin(II) 2-ethyl hexanoate as polymerization catalyst under monomer melt conditions at 130 °C (scheme 6), this method is also referred to as the "polymerization from" approach. For example, poly(D,L-lactide)-block-poly(ethylene glycol)-lys-urea-glu(allyl protected) obtained by such polymerization is then converted to poly(D,L-lactide)-block-poly(ethylene glycol)-lys-urea-glu by removal of the allyl protecting groups using organic base (morpholine) and tetrakis(triphenylphosphine) palladium (0) as catalyst (scheme 7). The deprotection reaction conditions are optimized with regards to molar equivalents of morpholine, palladium catalyst and reaction time to enable quantitative removal of allyl protecting groups (>98%, determined by NMR spectroscopy), without any measurable reduction in the molar mass (as determined by size exclusion chromatography and dilute solution viscometry) of the block copolymer.




Scheme 6. Synthesis of Poly(D,L-lactide)-b-PEG-lys-urea-glu(allyl protected) conjugate by ring opening polymerization of D,L-lactide under monomer melt conditions at 130 °C using HO-PEG-PEG-lys-urea-glu(allyl protected) as macroinitiator and tin(II) 2-ethylhexanoate as polymerization catalyst

[0030] This application also describes the removal of residual palladium from the functionalized diblock copolymer PLA-PEG-lys-urea-glu (PLA-PEG-TA). Scheme 8 shows the chemical structures of several commercially available resins used for scavenging palladium contaminants. Trimercaptotriazide (TMT) functional resin is preferred for the removal of palladium from PLA-PEG-lys-urea-glu samples with minimal loss of polymer yield in the palladium removal step. Yield loss is observed when resins functionalized with palladium binding moieties other than TMT are used. This is due to interaction between the resin bound palladium binding moieties and the TA in PLA-PEG-TA.



Scheme 7. Conversion of Poly(D,L-lactide)-b-PEG-lys-urea-glu(allyl protected) (PLA-PEG-TA(PRO)) to PLA-PEG-PEG-lys-urea-glu (PLA-PEG-TA) using tetrakis(triphenylphosphine) palladium (0) catalyst in morpholine/dichloromethane solution


[0031] This application also describes the covalent conjugation of targeting agents (TA's) in their native unprotected form under aqueous solution conditions to heterobifunctional poly(ethylene glycol). This method utilizes the high water solubility of the targeting moiety such as lys-urea-glu or other peptide based targeting ligands. The solubility properties of the PEG-lys-urea-glu conjugate are dominated by the poly(ethylene glycol) polymer. Thus, unlike lys-urea-glu, PEG-lys-urea-glu is soluble in common organic solvents including but not limited to dichloromethane, dimethyl formamide, tetrahydrofuran, chloroform, or dimethylsulfoxide. This enables covalent coupling of the PEG-lys-urea-glu conjugate to end functional poly(ester) to yield the desired Poly(ester)-PEG-lys-urea-glu (Poly(ester)-PEG-TA) under organic solvent conditions where lys-urea-glu prior to the PEG conjugation is insoluble or sparingly soluble. This approach is referred to as the "coupling to" approach. Complete dissolution of the end functional poly(ester) and the PEG-lys-urea-glu in a common solvent is critical to obtaining a high yield of the desired Poly(ester)-PEG-TA functional block copolymer.



Scheme 8. Chemical structures of commercially available palladium scavenging resins; preferred functionality for palladium removal from PLA-PEG-lys-urea-glu is trimercaptotriazide (TMT)


[0032] The PEG-lys-urea-glu is covalently coupled to an end functional poly(ester) using chemistries that proceed without side reactions with the carboxylic acid moieties of lys-urea-glu. For example, an α-azido-ω-carboxylic acid may be conjugated to the amino moiety of the lys-urea-glu by its reaction with the carboxy terminus of such PEG.

[0033] The targeting agent functional PEG, α-azido-ω-(lys-urea-glu)polyethylene glycol may be prepared by synthesis of a heterobifunctional precursor such as α-azido-ω-carboxy polyethylene glycol (N_3-PEG-CO_2H) from commercially available starting materials such as α-amino-ω-carboxy-poly(ethylene glycol) and for example 4-azidophenyl isothiocyanate, O-(2-azidoethyl)-O-[2-diglycolyl-amino)ethyl]heptaethylene glycol or azide-PEG4-NHS using standard conjugation methodologies (scheme 9). The heterobifunctional polymer, N_3-PEG-CO_2H is subsequently reacted with the amine functionality of lys-urea-glu under aqueous conditions using methods illustrated in scheme 10.




Scheme 9. Synthesis of N_3-PEG-CO_2H from commercially available starting materials using conventional chemistry techniques

Alternatively, N_3-PEG-NHS may be prepared by activation of the carboxy terminus of N_3-PEG-CO_2H under anhydrous organic solvent conditions such as in dichloromethane using organic soluble ethyldimethyl aminopropylcarbodiimide (EDC), N-hydroxysuccinimide (NHS) and diisopropyl ethylamine (DIEA) and subsequently purified by precipitation into anhydrous ether/hexane (70/30). The activated polymer (N_3-PEG-NHS) is then recovered by filtration and vacuum drying and stored in a dry environment under dry nitrogen (1ppm water dry glove box for 48 hours) prior to storage at -20 °C. N_3-PEG-NHS prepared by this method is then used to prepare N_3-PEG-lys-urea-glu as outlined in steps 6 though 10 of scheme 10.



Scheme 10. Synthesis of N_3-PEG-lys-urea-glu under aqueous conditions from N_3-PEG-CO_2H using pH adjustment to maximize the yield of desired product

[0034] As stated above, this application also describes the covalent coupling of N_3-PEG-lys-urea-glu to an end functional poly(ester) bearing a alkyne moiety at its α-terminus and a hydroxy terminus at its ω-terminus using well established "click" chemistry techniques such as using a copper sulfate catalyst under organic solvent conditions, for example in dimethylformamide (DMF) (scheme 11). This "click" chemistry methodology is particularly useful since the carboxylic acid functionalities of lys-urea-glu are not reactive towards the alkyne functionality of the poly(ester). Such orthogonal chemistry rules out possible side reactions and permits the use long reaction times between the poly(ester)-alkyne and N_3-PEG-lys-urea-glu. Furthermore, unlike amidation chemistry using for example Poly(ester)-NHS, "click" chemistry is not moisture sensitive, thus need for anhydrous conditions is not critical to ensure an acceptable degree of covalent conjugation that provides >80% end functionalization.



Scheme 11. Synthesis of PLA-PEG-lys-urea-glu by covalent conjugation of N_3-PEG-lys-urea-glu to alkyne-PLA in dimethylformamide using copper(I)bromide catalyst at 60ºC.

[0035] The "polymerization from" approach of scheme 6 and 7 has the following advantages:

1. Use of HO-PEG-TA(PRO) in the ring opening polymerization ensures no cross-reactivity between the functional groups of TA polymerization catalyst or monomer thereby avoiding loss of control over the polymerization and contaminating byproducts.
2. Absence of side reactions allows excellent control of the molecular weight and composition of the Poly(ester)-PEG-TA(PRO)
3. Adjustment of the composition of the monomer feed and the molar ratio of the initiator to monomer enables synthesis of the poly(ester) block of a wide range of desired compositions and molecular weights. The ratio or the PEG to the poly(ester) may also be varied at with ease.
4. The PLA-PEG-TA(PRO) is soluble in common dueterated organic solvents used for NMR spectroscopy such as chloroform-d, DMSO-d6, DMF-d7, or THF-d4. This enables NMR analysis of Poly(ester)-PEG-TA(PRO) providing quantitative information regarding critical polymer characteristics such as extent of TA(PRO) end group on Poly(ester)-PEG-TA(PRO) as well as absolute number average molecular weight (M_n). Provided relative molar mass (determined by for example size exclusion chromatography or inherent viscosity) of Poly(ester)-PEG-TA is equivalent to that of its protected precursor (Poly(ester)-PEG-TA(PRO)), the absolute M_n of Poly(ester)-PEG-TA(PRO) (determined by NMR spectroscopy) may be considered equal to that of its precursor. This enables precise determination

of polymer characteristic.

5. Precise determination of Poly(ester)-PEG-TA characteristic such as its absolute M_n and the extent of TA end group functionalization are critical for controlling the targeting properties of the nanoparticles made from Poly(ester)-PEG-TA. Such nanoparticles are prepared by blending known quantities of this functional polymer (Poly(ester)-PEG-TA) with non-functional polymer (Poly(ester)-PEG) to control the degree of targeting agent within the therapeutic nanoparticle.

[0036] The "polymerization from" approach of scheme 6 and 7 has the following shortcomings:

1. It requires the functional groups of the TA to be protected. This may require use of expensive and/or difficult to obtain starting materials when TA is based on 2 or more amino acid residues or nucleic acids containing side chain moieties that may interfere with the ring opening polymerization.

2. It necessitates removal of the protecting groups of TA(PRO) to yield the desired Poly(ester)-PEG-TA. The deprotection reaction may require use of a heavy metal catalyst that needs to be removed from the final product. This adding a purification step to the process that may in some cases be difficult to achieve with sufficient efficiency so as to provide a polymeric material of pharmaceutically acceptable purity.

[0037] The "coupling to" approach (that is not part of the invention) has the following advantages:

1. It does not require potentially expensive protected analogues of the targeting agent (TA(PRO)'s)

2. It does not require the deprotection of the TA(PRO) to obtain the desired Poly(ester)-PEG-TA polymer thereby avoiding associated shortcomings as described previously.

[0038] The "coupling to" approach has the following shortcomings:

1. It relies on coupling pre-made end functional poly(ester)s to PEG-TA, hence control over the composition and molecular weight of the poly(ester) requires synthesis of poly(ester)s of various desired properties in advance of the coupling reaction.


2. Coupling of macromolecular entities such as an end functional Poly(ester) and PEG-TA is slow due to poor diffusion characteristic of polymers and requires long reaction times at high reagents concentrations to ensure acceptable coupling efficiencies (>80%).

3. The method yields Poly(ester)-PEG-TA. Diblock copolymers bearing TA's as an end group are difficult to analyze by NMR spectroscopy due to differences in solubility characteristics of the poly(ester)-PEG polymer and the TA. Thus, quantitative analysis of end group functionality and absolute M_n is difficult using conventional methods such NMR spectroscopy.


[0039] In view of the advantages and shortcoming of the "polymerization from" and "coupling to" approaches, the latter is preferred over the former only when the TA(PRO) is expensive and/or difficult to obtain or the deprotection conditions are difficult or irreversibly contaminate the final polymeric product. Otherwise, the "polymerization from" approach is preferred due to easy of access to a large variety of polymer architectures and compositions as well as ease of analytical characterization of the Poly(ester)-PEG-TA(PRO) and hence the final product (Poly(ester)-PEG-TA) in cases where equivalence of polymer architecture may be established by other non-absolute yet dependable analytical methods.

[0040] The self-assembly of the poly(ester)-PEG-X diblock copolymers in aqueous medium yields nanoparticles comprising a hydrophobic core and a hydrophilic poly(ethylene glycol) corona (exterior). The hydrophobic core bears the bioactive/therapeutic agent while the hydrophilic corona presents the targeting agent on the nanoparticle surface and enables the nanoparticles to selectively bind to target sites (e.g., diseased tissue) via interaction of the targeting agent with a corresponding agent expressed at the target site.


[0041] Chemical Structures of abbreviations used:




GL 1




GL 2




GL 1P




GL 2P




EDC



NHS



DIEA



Pd Catalyst

BIOACTIVE MOIETIES/THERAPEUTIC AGENTS

[0042] As discussed above, therapeutic agents (bioactive moieties) can be incorporated into the hydrophobic nanoparticle core in aqueous medium or organic solvents and the nanoparticles can be, subsequently, purified. Bioactive agents (therapeutic agents) include, and are not limited to, therapeutic agents (*e.g.* anti-cancer agents), diagnostic agents (*e.g.* contrast agents; radionuclides; and fluorescent, luminescent, and magnetic moieties), prophylactic agents (*e.g.* vaccines), and/or nutraceutical agents (*e.g.* vitamins, minerals, *etc.*). As discussed herein, bioactive agents may be administered to an individual as disclosed herein. Exemplary therapeutic agents to be delivered in accordance with the present invention include, but are not limited to, small molecules (*e.g.* cytotoxic agents), nucleic acids (*e.g.,* siRNA, RNAi, and mircoRNA agents), proteins (*e.g.* antibodies), peptides, lipids, carbohydrates, hormones, metals, radioactive elements and compounds, drugs, vaccines, immunological agents, *etc.,* and/or combinations thereof. In some embod-

iments, the agent to be delivered is an agent useful in the treatment of cancer (*e.g.*, prostate cancer).

[0043] Some examples of therapeutic agents that can be delivered within the nanoparticles produced in accordance with the disclosed methods include, but are not limited to agents such as penicillins, aminopenicillins, penicillins in conjunction with penicillinase inhibitor and/or anti-fungal agents), cephalosporins, cephamycins and carbapenems, fluoroquinolones, tetracyclines, macrolides and aminoglycosides. Specific examples include, but are not limited to, erythromycin, bacitracin zinc, polymyxin, polymyxin B sulfates, neomycin, gentamycin, tobramycin, gramicidin, ciprofloxacin, trimethoprim, ofloxacin, levofloxacin, gatifloxacin, moxifloxacin, norfloxacin, sodium sulfacetamide, chloramphenicol, tetracycline, azithromycin, clarithyromycin, trimethoprim sulfate and bacitracin.

[0044] Yet other examples of therapeutic agents suitable for inclusion within the disclosed nanoparticles are non-steroidal (NSAIDs) and steroidal anti-inflammatory agents (generally referred to as anti inflammatory agents (including both COX-1 and COX-2 inhibitors)). Examples include, but are not limited to, corticosteroids, medrysone, prednisolone, prednisolone acetate, prednisolone sodium phosphate, fluormetholone, dexamethasone, dexamethasone sodium phosphate, betamethasone, fluoromethasone, antazoline, fluorometholone acetate, rimexolone, loteprednol etabonate, diclofenac (diclofenac sodium), ketorolac, ketorolac tromethamine, hydrocortisone, bromfenac, flurbiprofen, antazoline and xylometazoline.

[0045] Other therapeutic agents that can be incorporated into nanoparticles as disclosed herein include anti-histamines, mast cell stabilizers and other anti-allergy agents. Examples include, but are not limited, cromolyn sodium, lodoxamide tromethamine, olopatadine HCl, nedocromil sodium, ketotifen fumurate, levocabastine HCL, azelastine HCL, pemirolast (pemirolast potassium), epinastine HCL, naphazoline HCL, emedastine, antazoline, pheniramine, sodium cromoglycate, N-acetyl-aspartyl glutamic acid and amlexanox.

[0046] Other non-limiting examples of potentially suitable therapeutic agents for incorporation into nanoparticles include anti-cancer agents such as 5-fluorouracil (5-FU), CPT-11, 10-hydroxy-7-ethylcamptothecin (SN38), S-I capecitabine, ftorafur, 5'deoxyflurouridine, UFT, eniluracil, deoxycytidine, 5-azacytosine, 5-azadeoxycytosine, allopurinol, 2-chloroadenosine, aminopterin, methylene-10-deazaaminopterin (MDAM), oxaplatin, picoplatin, tetraplatin, satraplatin, platinum-DACH, ormaplatin, CI-973, JM-216, and analogs thereof, 9- aminocamptothecin, 10,11-methylenedioxycamptothecin, karenitecin, 9-nitrocamptothecin, TAS 103, L-phenylalanine mustard, ifosphamidemefosphamide, trophosphamide carmustine, epothilones A-E, tomudex, 6-mercaptopurine, 6-thioguanine, karenitecin, acyclovir, valacyclovir, ganciclovir, amantadine, rimantadine, lamivudine, zidovudine, bevacizumab, trastuzumab, rituximab,20-epi-1α, 25 dihydroxyvitamin D3, 4-ipomeanol, 5-ethynyluracil, 9-dihydrotaxol, abiraterone, acivicin, aclarubicin, acodazole hydrochloride, acronine, acylfiilvene, adecypenol, adozelesin, aldesleukin, all-tk antagonists, altretamine, ambamustine, ambomycin, ametantrone acetate, amidox, amifostine, aminoglutethimide, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, andrographolide, angiogenesis inhibitors, antagonist D, antagonist G, antarelix, anthramycin, anti-dorsalizdng morphogenetic protein-1, antiestrogen, antineoplaston, antisense oligonucleotides, aphidicolin glycinate, apoptosis gene modulators, apoptosis regulators, apurinic acid, ARA-CDP-DL-PTBA, arginine deaminase, asparaginase, asperlin, asulacrine, atamestane, atrimustine, axinastatin 1, axinastatin 2, axinastatin 3, azacitidine, azasetron, azatoxin, azatyrosine, azetepa, azotomycin, baccatin III derivatives, balanol, batimastat, benzochlorins, benzodepa, benzoylstaurosporine, beta lactam derivatives, beta-alethine, betaclamycin B, betulinic acid, BFGF inhibitor, bicalutamide, bisantrene, bisantrene hydrochloride, bisazuidinylspermine, bisnafide, bisnafide dimesylate, bistratene A, bizelesin, bleomycin, bleomycin sulfate, BRC/ABL antagonists, breflate, brequinar sodium, bropirimine, budotitane, busulfan, buthionine sulfoximine, cactinomycin, calcipotriol, calphostin C, calusterone, camptothecin derivatives, canarypox IL-2, capecitabine, caracemide, carbetimer, carboplatin, carboxamide-amino-triazole, carboxyamidotriazole, carest M3, carmustine, earn 700, cartilage derived inhibitor, carubicin hydrochloride, carzelesin, casein kinase inhibitors, castanosperrnine, cecropin B, cedefingol, cetrorelix, chlorambucil, chlorins, chloroquinoxaline sulfonamide, cicaprost, cirolemycin, cisplatin, cis-porphyrin, cladribine, clomifene analogs, clotrimazole, collismycin A, collismycin B, combretastatin A4, combretastatin analog, conagenin, crambescidin 816, crisnatol, crisnatol mesylate, cryptophycin 8, cryptophycin A derivatives, curacin A, cyclopentanthraquinones, cyclophosphamide, cycloplatam, cypemycin, cytarabine, cytarabine ocfosfate, cytolytic factor, cytostatin, dacarbazine, dacliximab, dactinomycin, daunorubicin hydrochloride, decitabine, dehydrodidemnin B, deslorelin, dexifosfamide, dexormaplatin, dexrazoxane, dexverapamil, dezaguanine, dezaguanine mesylate, diaziquone, didemnin B, didox, diethyhiorspermine, dihydro-5-azacytidine, dioxamycin, diphenyl spiromustine, docetaxel, docosanol, dolasetron, doxifluridine, doxorubicin, doxorubicin hydrochloride, droloxifene, droloxifene citrate, dromostanolone propionate, dronabinol, duazomycin, duocannycin SA, ebselen, ecomustine, edatrexate, edelfosine, edrecolomab, eflomithine, eflomithine hydrochloride, elemene, elsarnitrucin, emitefur, enloplatin, enpromate, epipropidine, epirubicin, epirubicin hydrochloride, epristeride, erbulozole, erythrocyte gene therapy vector system, esorubicin hydrochloride, estramustine, estramustine analog, estramustine phosphate sodium, estrogen agonists, estrogen antagonists, etanidazole, etoposide, etoposide phosphate, etoprine, exemestane, fadrozole, fadrozole hydrochloride, fazarabine, fenretinide, filgrastim, finasteride, flavopiridol, flezelastine, floxuridine, fluasterone, fludarabine, fludarabine phosphate, fluorodaunorunicin hydrochloride, fluorouracil, flurocitabine, forfenimex, formestane, fosquidone, fostriecin, fostriecin sodium, fotemustine, gadolinium texaphyrin, gallium nitrate, galocitabine, ganirelix, gelatinase inhibitors, gemcitabine, gemcitabine

hydrochloride, glutathione inhibitors, hepsulfam, heregulin, hexamethylene bisacetamide, hydroxyurea, hypericin, ibandronic acid, idarubicin, idarubicin hydrochloride, idoxifene, idramantone, ifosfamide, ihnofosine, ilomastat, imidazoacridones, imiquimod, immunostimulant peptides, insulin-like growth factor-1 receptor inhibitor, interferon agonists, interferon alpha-2A, interferon alpha-2B, interferon alpha-N1, interferon alpha-N3, interferon beta-IA, interferon gamma-IB, interferons, interleukins, iobenguane, iododoxorubicin, iproplatm, irinotecan, irinotecan hydrochloride, iroplact, irsogladine, isobengazole, isohomohalicondrin B, itasetron, jasplakinolide, kahalalide F, lamellarin-N triacetate, lanreotide, lanreotide acetate, leinamycin, lenograstim, lentinan sulfate, leptolstatin, letrozole, leukemia inhibiting factor, leukocyte alpha interferon, leuprolide acetate, leuprolide/estrogen/progesterone, leuprorelin, levamisole, liarozole, liarozole hydrochloride, linear polyamine analog, lipophilic disaccharide peptide, lipophilic platinum compounds, lissoclinamide, lobaplatin, lombricine, lometrexol, lometrexol sodium, lomustine, lonidamine, losoxantrone, losoxantrone hydrochloride, lovastatin, loxoribine, lurtotecan, lutetium texaphyrin lysofylline, lytic peptides, maitansine, mannostatin A, marimastat, masoprocol, maspin, matrilysin inhibitors, matrix metalloproteinase inhibitors, maytansine, mechlorethamine hydrochloride, megestrol acetate, melengestrol acetate, melphalan, menogaril, merbarone, mercaptopurine, meterelin, methioninase, methotrexate, methotrexate sodium, metoclopramide, metoprine, meturedepa, microalgal protein kinase C uihibitors, MIF inhibitor, mifepristone, miltefosine, mirimostim, mismatched double stranded RNA, mitindomide, mitocarcin, mitocromin, mitogillin, mitoguazone, mitolactol, mitomalcin, mitomycin, mitomycin analogs, mitonafide, mitosper, mitotane, mitotoxin fibroblast growth factor-saporin, mitoxantrone, mitoxantrone hydrochloride, mofarotene, molgramostim, monoclonal antibody, human chorionic gonadotrophin, monophosphoryl lipid a/myobacterium cell wall SK, mopidamol, multiple drug resistance gene inhibitor, multiple tumor suppressor 1-based therapy, mustard anticancer agent, mycaperoxide B, mycobacterial cell wall extract, mycophenolic acid, myriaporone, n-acetyldinaline, nafarelin, nagrestip, naloxone/pentazocine, napavin, naphterpin, nartograstim, nedaplatin, nemorubicin, neridronic acid, neutral endopeptidase, nilutamide, nisamycin, nitric oxide modulators, nitroxide antioxidant, nitrullyn, nocodazole, nogalamycin, n-substituted benzamides, 06-benzylguanine, octreotide, okicenone, oligonucleotides, onapristone, ondansetron, oracin, oral cytokine inducer, ormaplatin, osaterone, oxaliplatin, oxaunomycin, oxisuran, paclitaxel, paclitaxel analogs, paclitaxel derivatives, palauamine, palmitoylrhizoxin, pamidronic acid, panaxytriol, panomifene, parabactin, pazelliptine, pegaspargase, peldesine, peliomycin, pentamustine, pentosan polysulfate sodium, pentostatin, pentrozole, peplomycin sulfate, perflubron, perfosfamide, perillyl alcohol, phenazinomycin, phenylacetate, phosphatase inhibitors, picibanil, pilocarpine hydrochloride, pipobroman, piposulfan, pirarubicin, piritrexim, piroxantrone hydrochloride, placetin A, placetin B, plasminogen activator inhibitor, platinum complex, platinum compounds, platinum-triamine complex, plicamycin, plomestane, porfimer sodium, porfiromycin, prednimustine, procarbazine hydrochloride, propyl bis-acridone, prostaglandin J2, prostatic carcinoma antiandrogen, proteasome inhibitors, protein A-based immune modulator, protein kinase C inhibitor, protein tyrosine phosphatase inhibitors, purine nucleoside phosphorylase inhibitors, puromycin, puromycin hydrochloride, purpurins, pyrazorurin, pyrazoloacridine, pyridoxylated hemoglobin polyoxyethylene conjugate, RAF antagonists, raltitrexed, ramosetron, RAS farnesyl protein transferase inhibitors, RAS inhibitors, RAS-GAP inhibitor, retelliptine demethylated, rhenium RE 186 etidronate, rhizoxin, riboprine, ribozymes, RH retinarnide, RNAi, rogletimide, rohitukine, romurtide, roquinimex, rubiginone BI, ruboxyl, safingol, safingol hydrochloride, saintopin, sarcnu, sarcophytol A, sargramostim, SDI1 mimetics, semustine, senescence derived inhibitor 1, sense oligonucleotides, signal transduction inhibitors, signal transduction modulators, simtrazene, single chain antigen binding protein, sizofiran, sobuzoxane, sodium borocaptate, sodium phenylacetate, solverol, somatomedin binding protein, sonermin, sparfosafe sodium, sparfosic acid, sparsomycin, spicamycin D, spirogermanium hydrochloride, spiromustine, spiroplatin, splenopentin, spongistatin 1, squalamine, stem cell inhibitor, stem-cell division inhibitors, stipiamide, streptonigrin, streptozocin, stromelysin inhibitors, sulfinosine, sulofenur, superactive vasoactive intestinal peptide antagonist, suradista, suramin, swainsonine, synthetic glycosaminoglycans, talisomycin, tallimustine, tamoxifen methiodide, tauromustine, tazarotene, tecogalan sodium, tegafur, tellurapyrylium, telomerase inhibitors, teloxantrone hydrochloride, temoporfin, temozolomide, teniposide, teroxirone, testolactone, tetrachlorodecaoxide, tetrazomine, thaliblastine, thalidomide, thiamiprine, thiocoraline, thioguanine, thiotepa, thrombopoietin, thrombopoietin mimetic, thymalfasin, thymopoietin receptor agonist, thymotrinan, thyroid stimulating hormone, tiazofurin, tin ethyl etiopurpurin, tirapazamine, titanocene dichloride, topotecan hydrochloride, topsentin, toremifene, toremifene citrate, totipotent stem cell factor, translation inhibitors, trestolone acetate, tretinoin, triacetyluridine, triciribine, triciribine phosphate, trimetrexate, trimetrexate glucuronate, triptorelin, tropisetron, tubulozole hydrochloride, turosteride, tyrosine kinase inhibitors, tyrphostins, UBC inhibitors, ubenimex, uracil mustard, uredepa, urogenital sinus-derived growth inhibitory factor, urokinase receptor antagonists, vapreotide, variolin B, velaresol, veramine, verdins, verteporfin, vinblastine sulfate, vincristine sulfate, vindesine, vindesine sulfate, vinepidine sulfate, vinglycinate sulfate, vinleurosine sulfate, vinorelbine, vinorelbine tartrate, vinrosidine sulfate, vinxaltine, vinzolidine sulfate, vitaxin, vorozole, zanoterone, zeniplatin, zilascorb, zinostatin, zinostatin stimalamer, or zorubicin hydrochloride and combinations thereof.

[0047] In one embodiment, the nanoparticles of this invention can contain siRNA as a therapeutic agent. Preferably, the siRNA molecule has a length from about 10-50 or more nucleotides. More preferably, the siRNA molecule has a length from about 15-45 nucleotides. Even more preferably, the siRNA molecule has a length from about 19-40 nucleotides. Even more preferably, the siRNA molecule has a length of from about 21-23 nucleotides. The siRNA of the

invention preferably mediates RNAi against a target mRNA. The siRNA molecule can be designed such that every residue is complementary to a residue in the target molecule. Alternatively, one or more substitutions can be made within the molecule to increase stability and/or enhance processing activity of said molecule. Substitutions can be made within the strand or can be made to residues at the ends of the strand.

[0048] siRNA molecules used as therapeutic agents in the disclosed nanoparticles can be modified to improve stability either *in vivo* or *in vitro.* In order to enhance the stability, the 3'-residues may be stabilized against degradation, *e.g.,* they may be selected such that they consist of purine nucleotides, particularly adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, *e.g.,* substitution of uridine by 2'-deoxythymidine is tolerated and does not affect the efficiency of RNA interference. For example, the absence of a 2'hydroxyl may significantly enhance the nuclease resistance of the siRNAs.

[0049] Commercially available design tools and kits, such as those available from Ambion, Inc. (Austin, TX), and the Whitehead Institute of Biomedical Research at MIT (Cambridge, MA) allow for the design and production of siRNA. By way of example, a desired mRNA sequence can be entered into a sequence program that will generate sense and antisense target strand sequences. These sequences can then be entered into a program that determines the sense and antisense siRNA oligonucleotide templates. The programs can also be used to add, *e.g.,* hairpin inserts or T1 promoter primer sequences. Kits also can then be employed to build siRNA expression cassettes.

[0050] In various embodiments, siRNAs are synthesized *in vivo, in situ,* and *in vitro.* Endogenous RNA polymerase of the cell may mediate transcription *in vivo* or *in situ,* or cloned RNA polymerase can be used for transcription *in vivo* or *in vitro.* For transcription from a transgene *in vivo* or an expression construct, a regulatory region (*e.g.*, promoter, enhancer, silencer, splice donor and acceptor, polyadenylation) may be used to transcribe the siRNAs. Inhibition may be targeted by specific transcription in an organ, tissue, or cell type; stimulation of an environmental condition (*e.g.*, infection, stress, temperature, chemical inducers); and/or engineering transcription at a developmental stage or age. A transgenic organism that expresses siRNAs from a recombinant construct may be produced by introducing the construct into a zygote, an embryonic stem cell, or another multipotent cell derived from the appropriate organism.


[0051] In one embodiment, the siRNA molecules target mRNA encoding at least one a cellular protein (*e.g.,* a nuclear, cytoplasmic, transmembrane, or membrane-associated protein). In another embodiment, the siRNA molecules target mRNA encoding one or more extracellular protein (*e.g.,* an extracellular matrix protein or secreted protein). Thus, target mRNA can encode developmental proteins (*e.g.,* adhesion molecules, cyclin kinase inhibitors, Wnt family members, Pax family members, Winged helix family members, Hox family members, cytokines/lymphokines and their receptors, growth/differentiation factors and their receptors, neurotransmitters and their receptors); oncogene-encoded proteins (*e.g.,* ABLI, BCLI, BCL2, BCL6, CBFA2. CBL, CSFIR, ERBA, ERBB, EBRB2, ERBB2, ERBB3, ETSI, ETSI, ETV6, FGR, FOS, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, MYB, MYC, MYCLI, MYCN, NRAS, PIM 1, PML, RET, SRC, TALI, TCL3, and YES); tumor suppressor proteins (*e.g.*, APC, BRCA1, BRCA2, MADH4, MCC, NF 1, NF2, RB 1, TP53, or WTI); and enzymes (*e.g.*, ACC synthases and oxidases, ACP desaturases and hydroxylases, ADPglucose pyrophorylases, acetylases and deacetylases, ATPases, alcohol dehydrogenases, amylases, amyloglucosidases, catalases, cellulases, chalcone synthases, chitinases, cyclooxygenases, decarboxylases, dextrinases, DNA and RNA polymerases, galactosidases, glucanases, glucose oxidases, granule-bound starch synthases, GTPases, helicases, hemicellulases, integrases, inulinases, invertases, isomerases, kinases, lactases, lipases, lipoxygenases, lysozymes, nopaline synthases, octopine synthases, pectinesterases, peroxidases, phosphatases, phospholipases, phosphorylases, phytases, plant growth regulator synthases, polygalacturonases, proteinases and peptidases, pullanases, recombinases, reverse transcriptases, RUBISCOs, topoisomerases or xylanases). Target mRNA can also encode proteins involved in tumor growth (including vascularization) or in metastatic activity or potential (e.g., cell suface receptors and their ligands). Target mRNA can also encode one or more secreted protein, cell cycle regulatory protein, gene regulatory protein, apoptosis regulatory protein, or proteins involved in the immune response, inflammation, complement cascade, or clotting systems. Additional examples of target mRNA against which siRNA constructs can designed include *c-myc, c-myb, mdm2, PKA-I (protein kinase A type I), Ras,* c-Raf kinase, CDC25 phosphatases, cyclins, cyclin dependent kinases (cdks), telomerase, *PDGF*/*sis* and *mos.* siRNA can also be used to target the mRNA encoded by a fusion gene that results from chromosomal translocation, for example, the *Bcr*/*Abl* fusion oncogene. siRNA can also be targeted against mRNA encoding proteins such as cyclin dependent kinases, proliferating cell nuclear antigen (PCNA), transforming growth factor-beta (TGF-beta), nuclear factor kappa B (NF-κB), E2F, HER-2/neu, PKA, TGF-alpha, EGFR, TGF-beta, IGFIR, P12, MDM2, VEGF, MDR, transferring, ferritin, ferritin receptor, transferrin receptor, IRE, C-fos, HSP27, metallothionein.

TARGETING AGENTS


[0052] As noted above, nanoparticles produced by the instant invention can also incorporate one or more targeting agent via the functionalized PEG moieties. Suitable targeting agents include, for example, antibodies and polypeptides that bind to polypeptides that are commonly overexpressed by tumor or cancer cells. Non-limiting examples of such

polypeptides are epidermal growth factor receptor (EGFR), somatostatin receptor (SSTR), insulin-like growth factor receptor, folic acid-receptor, HER2 receptor, interleukin-13 receptor, gastrin-releasing peptide receptor, CD30, vasoactive intestinal peptide receptor, gastrin receptor, prostate-specific antigen, and the estrogen receptor.


[0053] Another example of a targeting agents suitable for coupling to the disclosed nanoparticles via functionalized PEG are small molecule ligands. Such small molecule ligands can be used to target cancers that express particular target proteins. For example, for tumors or cancers that express prostate specific membrane antigen (PSMA) (including, but not limited to, prostate cancer, non-small cell lung cancer, colorectal carcinoma, and glioblastoma, and solid tumors expressing PSMA in the tumor neovasculature), PSMA ligands can be used. In some embodiments, the low-molecular weight PSMA ligand is of the Formulae I, II, III or IV:




I



II



III



IV


,

and enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof;
wherein
m and n are each, independently, 0, 1, 2 or 3;
p is 0 or 1;
R^1, R^2, R^4 and R^5 are each, independently, selected from the group consisting of substituted or unsubstituted alkyl (*e.g.,* C_{1-10}-alkyl, C_{1-6}-alkyl, or C_{1-4}-alkyl), substituted or unsubstituted aryl (*e.g.,* phenyl or pyrdinyl), and any combination thereof; and
R^3 is H or C_{1-6}-alkyl (*e.g.,* CH_3).


[0054] For compounds of Formulae I, II, III and IV, R^1, R^2, R^4 and R^5 comprise points of attachment to the nanoparticle within the PEG portion of the nanoparticle. The point of attachment may be formed by a covalent bond, ionic bond, hydrogen bond, a bond formed by adsorption including chemical adsorption and physical adsorption, a bond formed from van der Waals bonds, or dispersion forces. For example, if R^1, R^2, R^4 or R^3 are defined as an aniline or C_{1-6}-alkyl-NH_2 group, any hydrogen (*e.g.,* an amino hydrogen) of these functional groups could be removed such that the low-molecular weight PSMA ligand is covalently bound to the polymeric matrix (*e.g.,* the PEG-block of the polymeric matrix) of the nanoparticle. As used herein, the term "covalent bond" refers to a bond between two atoms formed by sharing at least one pair of electrons.

[0055] In particular embodiments of the Formulae I, II, III or IV, R^1, R^2, R^4 and R^5 are each, independently, C_{1-6}-alkyl or phenyl, or any combination of C_{1-6}-alkyl or phenyl, which are independently substituted one or more times with OH, SH, NH_2, or CO_2H, and wherein the alkyl group may be interrupted by N(H), S or O. In another embodiment, R^1, R^2, R^4 and R^5 are each, independently, CH_2-Ph, $(CH_2)_2$-SH, CH_2-SH, $(CH_2)_2C(H)(NH_2)CO_2H$, $CH_2C(H)(NH_2)CO_2H$, $CH(NH_2)CH_2CO_2H$, $(CH_2)_2C(H)(SH)CO_2H$, CH_2-N(H)-Ph, O-CH_2-Ph, or O-$(CH_2)_2$-Ph, wherein each Ph may be independently substituted one or more times with OH, NH_2, CO_2H or SH. For these formulae, the NH_2, OH or SH groups serve as the point of covalent attachment to the nanoparticle (*e.g.*, -N(H)-PEG, -O-PEG, or -S-PEG).


[0056] In still another embodiment, the low-molecular weight PSMA ligand is selected from the group consisting of



,




,






,

and




and enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof, and wherein the NH_2, OH or SH groups serve as the point of covalent attachment to the nanoparticle (*e.g.*, -N(H)-PEG, -O-PEG, or-S-PEG).

[0057] In another embodiment, the low-molecular weight PSMA ligand is selected from the group consisting of





,

,


and



,

and enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof, wherein R is independently selected from the group consisting of NH_2, SH, OH, CO_2H, C_{1-6}-alkyl that is substituted with NH_2, SH, OH or CO_2H, and phenyl that is substituted with NH_2, SH, OH or CO_2H, and wherein R serves as the point of covalent attachment to the nanoparticle (*e.g.*, -N(H)-PEG, -S-PEG, -O-PEG, or CO_2-PEG).

[0058] In another embodiment, the low-molecular weight PSMA ligand is selected from the group consisting of



,

,

,

and


,


and enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof, wherein the NH_2 or CO_2H groups serve as the point of covalent attachment to the nanoparticle (*e.g.*, -N(H)-PEG, or CO_2-PEG). These compounds may be further substituted with NH_2, SH, OH, CO_2H, C_{1-6}-alkyl that is substituted with NH_2, SH, OH or CO_2H, or phenyl that is substituted with NH_2, SH, OH or CO_2H, wherein these functional groups can also serve as the point of covalent attachment to the nanoparticle.

[0059] In another embodiment, the low-molecular weight PSMA ligand is




and enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof, wherein n is 1, 2, 3, 4, 5 or 6. For this ligand, the NH_2 group serves as the point of covalent attachment to the nanoparticle (*e.g.,* -N(H)-PEG).

[0060] In still another embodiment, the low-molecular weight PSMA ligand is




and enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Particularly, the butyl-amine compound has the advantage of ease of synthesis, especially because of its lack of a benzene ring. Furthermore, without wishing to be bound by theory, the butyl-amine compound will likely break down into naturally occurring molecules (*i.e.,* lysine and glutamic acid), thereby minimizing toxicity concerns.

[0061] For these ligands, the NH_2 groups serve as the point of covalent attachment to the nanoparticle (*e.g.*, -N(H)-PEG). Accordingly, the present invention provides the low-molecular weight PSMA ligands shown above, wherein the amine substituents of the compounds are covalently bound to poly(ethylene glycol), *e.g.,* the



or compounds:



wherein n is 20 to 1720.

[0062] Another aspect of the invention provides for a PEG polymer conjugated to a targeting agents and/or bioactive moieties/therapeutic agents as disclosed herein.

NANOPARTICLE COMPOSITIONS AND USES THEREOF

[0063] The nanoparticles produced in accordance with the disclosed methods can be administered alone or in a composition. When nanoparticles are administered as a composition, the composition can be a pharmaceutical (e.g., physiologically acceptable) composition. The composition comprises a carrier (e.g., a pharmaceutically or physiologically acceptable carrier) and the nanoparticles. Any suitable carrier (e.g., water, saline, and PBS) can be used within the context of the invention, and such carriers are well known in the art. The choice of carrier will be determined, in part, by the particular site to which the composition is to be administered and the particular method used to administer the composition. Suitable carriers, as well as other components suitable for use in the composition of the invention, are known in the art (e.g., Remington's Pharmaceutical Sciences, 17th ed., (Mack Publishing Company, Philadelphia, Pa.: 1985)). Additionally, the composition can comprise additional active agents, such as anti-cancer/chemotherapeutic agents.

[0064] The nanoparticles and composition thereof can be administered to a subject to treat or prevent particular disorders and diseases. Non-limiting examples of diseases or disorders that can be treated in accordance with the subject invention include cancer, such as lung cancer, breast cancer, prostate cancer, head and neck cancer, ovarian cancer, skin cancer, testicular cancer, pancreatic cancer, esophageal cancer, colorectal cancer, kidney cancer, cervical cancer, gastrointestinal cancer, and combinations thereof. The nanoparticles or the composition thereof preferably are administered to the subject in a therapeutically effective amount.

[0065] A therapeutically effective amount refers to an amount of the nanoparticles necessary to treat or prevent the particular disease or disorder. For example nanoparticles disclosed herein can be used to inhibit tumor growth, inhibit or reduce proliferation, invasiveness, or metastasis of tumor or cancer cells, slow the growth of tumors or cancers or reduce the size of tumors.

[0066] Any route of administration can be used to deliver the nanoparticles to the subject. Suitable administration routes include intramuscular injection, transdermal administration, inhalation, topical application to tissue (e.g., tumor/cancer tissue), intratumoral administration, and parenteral administration (e.g., intravenous, peritoneal, intraarterial, subcutaneous, rectal, or vaginal, administration). An appropriate administration route easily can be determined by those skilled in the art.

[0067] As discussed above, compositions comprising nanoparticles can be useful in the treatment or prevention or amelioration of one or more symptoms of cancer, particularly cancers that express prostate specific membrane antigen (PSMA). These cancers include, but are not limited to, prostate cancer, non-small cell lung cancer, colorectal carcinoma, and glioblastoma, and solid tumors expressing PSMA in the tumor neovasculature.

[0068] Various aspects of the present disclosure include:

1. A method of preparing a nanoparticle comprising:

   providing a targeting agent;
   providing a functionalized poly(ethylene glycol) (PEG) polymer;
   providing a targeting agent ligand;
   reacting the functionalized poly(ethylene glycol) polymer with the targeting agent to form a targeting agent-PEG polymer complex; and
   mixing the targeting agent-PEG polymer complex with a second polymer and a therapeutic agent to form a nanoparticle, wherein:

      the PEG polymer has a molecular weight of between 1,000-20,000 Da (*e.g.,* 5,000-20,000, *e.g.,* 10,000-20,000) and, in some specific embodiments, 5000 Da; and the second polymer has a molecular weight of 5,000-100,000 Da (*e.g.,* 20,000-70,000, *e.g.,* 20,000-50,000), or in some specific embodiments, 15,000-30,000 Da;

2. The method of embodiment 1, wherein the poly(ethylene glycol) is hetero-bifunctional and said targeting agent is covalently bound to the α terminus of said poly(ethylene glycol) and at least one polymerization initiating functional group is present on the ω terminus of said poly(ethylene glycol);

3. The method of embodiment 2, wherein said at least one polymerization initiating functional group is a hydroxyl (-OH) group or an amine ($-NH_2$) group at the free ω terminus;

4. The method of embodiment 1, 2 or 3, wherein the second polymer comprises a blend of two or more polymers and contains at least one functional group that reacts the functional group present at the free ω terminus of said poly(ethylene glycol) and said at least one functional group of said blend of two or more polymers is a hydroxyl

group, a NHS group or an amine group;

5. The method of embodiment 1, wherein the second polymer or the copolymer is a polyester copolymer that contains at least one functional group selected from a hydroxyl group, a NHS group or an amine group and that reacts the functional group present at the free ω terminus of said poly(ethylene glycol);

6. The method of embodiment 4, wherein the second polymer or the copolymer is a polyester copolymer that contains at least one functional group selected from a hydroxyl group, a NHS group or an amine group and that reacts the functional group present at the free co terminus of said poly(ethylene glycol);

7. The method of embodiment 6, wherein said polyester copolymer comprises a heteropolymer or a homopolymer;

8. The method of embodiment 6, wherein said heteropolymer comprises lactic acid and glycolic acid units or poly(lactic acid-co-glycolic acid) and poly(lactide-co-glycolide) units (PLGA); and said homopolymer comprises glycolic acid units (PGA), lactic acid units (PLA), poly-L-lactic acid units, poly-D-lactic acid units, poly-D,L-lactic acid units, poly-L-lactide units, poly-D-lactide units or poly-D,L-lactide units;

9. The method of embodiment 6, wherein said polyester copolymer is selected from polyhydroxyacids; PEGylated polymers and copolymers of lactide units and glycolide units, PEGylated PLA, PEGylated PGA, PEGylated PLGA, polyanhydrides, poly(ortho ester) PEGylated poly(ortho ester), poly(caprolactone), PEGylated poly(caprolactone), polylysine, PEGylated polylysine, poly(ethylene inline), PEGylated poly(ethylene imine), poly(L-lactide-co-L-lysine), poly(serine ester), poly(4-hydroxy-L-proline ester), poly[a-(4-aminobutyl)-L-glycolic acid] or derivatives thereof;

10. The method of embodiment 1, wherein free carboxylic acid groups or free hydroxyl groups on said targeting agent are protected prior to reacting the functionalized poly(ethylene glycol) polymer with the targeting agent to form a targeting agent-PEG polymer complex;

11. The method of embodiment 4, wherein said functional group of said second polymer is an amine group that reacts with a hydroxyl group or carboxylic acid group on said targeting agent-PEG complex;

12. The method of embodiment 4, wherein said functional group of said second polymer is a hydroxyl group or an NHS group that reacts with an amine group on said targeting agent-PEG complex;

13. The method of embodiment 6, wherein said functional group of said second polymer or said copolymer is an amine group that reacts with a hydroxyl group or carboxylic acid group on said targeting agent-PEG complex;

14. The method of embodiment 6, wherein said functional group of said second polymer or said copolymer is a NHS or hydroxyl group that reacts with an amine group on said targeting agent-PEG complex;

15. The method of embodiments 1-14, wherein said second polymer is a blend of at least two polymers which can be the same or different polymer, wherein the first of said at least two polymers contains at least one hydroxyl group or an NHS group as a functional group and the second of said at least two polymers contains at least one amine group as said functional group;

16. The method of embodiment 1-15, wherein said therapeutic agent is an antibiotic, anti-cancer agent, antiviral agent, anti-inflammatory agent a diagnostic agent, a vaccine antigen or a nutraceutical;

17. The method of embodiment 16, wherein said therapeutic agent is/are penicillins, aminopenicillins, penicillins in conjunction with penicillinase inhibitor and/or anti-fungal agents, cephalosporins, cephamycins, carbapenems, fluoroquinolones, tetracyclines, macrolides, aminoglycosides, erythromycin, bacitracin zinc, polymyxin, polymyxin B sulfates, neomycin, gentamycin, tobramycin, gramicidin, ciprofloxacin, trimethoprim, ofloxacin, levofloxacin, gatifloxacin, moxifloxacin, norfloxacin, sodium sulfacetamide, chloramphenicol, tetracycline, azithromycin, clarithyromycin, trimethoprim sulfate, bacitracin, corticosteroids, medrysone, prednisolone, prednisolone acetate, prednisolone sodium phosphate, fluormetholone, dexamethasone, dexamethasone sodium phosphate, betamethasone, fluoromethasone, antazoline, fluorometholone acetate, rimexolone, loteprednol etabonate, diclofenac (diclofenac sodium), ketorolac, ketorolac tromethamine, hydrocortisone, bromfenac, flurbiprofen, antazoline, xylometazoline, cromolyn sodium, lodoxamide tromethamine, olopatadine HCl, nedocromil sodium, ketotifen fumurate, levocabastine HCL, azelastine HCL, pemirolast (pemirolast potassium), epinastine HCL, naphazoline HCL, emedastine, antazoline,

pheniramine, sodium cromoglycate, N-acetyl-aspartyl glutamic acid, amlexanox, 5-fluorouracil (5-FU), CPT-11, 10-hydroxy-7-ethylcamptothecin (SN38), S-I capecitabine, ftorafur, 5'deoxyflurouridine, UFT, eniluracil, deoxycytidine, 5-azacytosine, 5-azadeoxycytosine, allopurinol, 2-chloroadenosine, aminopterin, methylene-10-deazaaminopterin (MDAM), oxaplatin, picoplatin, tetraplatin, satraplatin, platinum-DACH, ormaplatin, CI-973, JM-216, and analogs thereof, 9-aminocamptothecin, 10,11-methylenedioxycamptothecin, karenitecin, 9-nitrocamptothecin, TAS 103, L-phenylalanine mustard, ifosphamidemefosphamide, trophosphamide carmustine, epothilones A-E, tomudex, 6-mercaptopurine, 6-thioguanine, karenitecin, acyclovir, valacyclovir, ganciclovir, amantadine, rimantadine, lamivudine, zidovudine, bevacizumab, trastuzumab, rituximab,20-epi-1α, 25 dihydroxyvitamin D3, 4-ipomeanol, 5-ethynyluracil, 9-dihydrotaxol, abiraterone, acivicin, aclarubicin, acodazole hydrochloride, acronine, acylfiilvene, adecypenol, adozelesin, aldesleukin, all-tk antagonists, altretamine, ambamustine, ambomycin, ametantrone acetate, amidox, amifostine, aminoglutethimide, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, andrographolide, angiogenesis inhibitors, antagonist D, antagonist G, antarelix, anthramycin, anti-dorsalizdng morphogenetic protein-1, antiestrogen, antineoplaston, antisense oligonucleotides, aphidicolin glycinate, apoptosis gene modulators, apoptosis regulators, apurinic acid, ARA-CDP-DL-PTBA, arginine deaminase, asparaginase, asperlin, asulacrine, atamestane, atrimustine, axinastatin 1, axinastatin 2, axinastatin 3, azacitidine, azasetron, azatoxin, azatyrosine, azetepa, azotomycin, baccatin III derivatives, balanol, batimastat, benzochlorins, benzodepa, benzoylstaurosporine, beta lactam derivatives, beta-alethine, betaclamycin B, betulinic acid, BFGF inhibitor, bicalutamide, bisantrene, bisantrene hydrochloride, bisazuidinylspermine, bisnafide, bisnafide dimesylate, bistratene A, bizelesin, bleomycin, bleomycin sulfate, BRC/ABL antagonists, breflate, brequinar sodium, bropirimine, budotitane, busulfan, buthionine sulfoximine, cactinomycin, calcipotriol, calphostin C, calusterone, camptothecin derivatives, canarypox IL-2, capecitabine, caraceraide, carbetimer, carboplatin, carboxamide-amino-triazole, carboxyamidotriazole, carest M3, carmustine, earn 700, cartilage derived inhibitor, carubicin hydrochloride, carzelesin, casein kinase inhibitors, castanospermine, cecropin B, cedefingol, cetrorelix, chlorambucil, chlorins, chloroquinoxaline sulfonamide, cicaprost, cirolemycin, cisplatin, cis-porphyrin, cladribine, clomifene analogs, clotrimazole, collismycin A, collismycin B, combretastatin A4, combretastatin analog, conagenin, crambescidin 816, crisnatol, crisnatol mesylate, cryptophycin 8, cryptophycin A derivatives, curacin A, cyclopentanthraquinones, cyclophosphamide, cycloplatam, cypemycin, cytarabine, cytarabine ocfosfate, cytolytic factor, cytostatin, dacarbazine, dacliximab, dactinomycin, daunorubicin hydrochloride, decitabine, dehydrodidemnin B, deslorelin, dexifosfamide, dexormaplatin, dexrazoxane, dexverapamil, dezaguanine, dezaguanine mesylate, diaziquone, didemnin B, didox, diethyhiorspermine, dihydro-5-azacytidine, dioxamycin, diphenyl spiromustine, docetaxel, docosanol, dolasetron, doxifluridine, doxorubicin, doxorubicin hydrochloride, droloxifene, droloxifene citrate, dromostanolone propionate, dronabinol, duazomycin, duocannycin SA, ebselen, ecomustine, edatrexate, edelfosine, edrecolomab, eflomithine, eflomithine hydrochloride, elemene, elsarnitrucin, emitefur, enloplatin, enpromate, epipropidine, epirubicin, epirubicin hydrochloride, epristeride, erbulozole, erythrocyte gene therapy vector system, esorubicin hydrochloride, estramustine, estramustine analog, estramustine phosphate sodium, estrogen agonists, estrogen antagonists, etanidazole, etoposide, etoposide phosphate, etoprine, exemestane, fadrozole, fadrozole hydrochloride, fazarabine, fenretinide, filgrastim, finasteride, flavopiridol, flezelastine, floxuridine, fluasterone, fludarabine, fludarabine phosphate, fluorodaunorunicin hydrochloride, fluorouracil, flurocitabine, forfenimex, formestane, fosquidone, fostriecin, fostriecin sodium, fotemustine, gadolinium texaphyrin, gallium nitrate, galocitabine, ganirelix, gelatinase inhibitors, gemcitabine, gemcitabine hydrochloride, glutathione inhibitors, hepsulfam, heregulin, hexamethylene bisacetamide, hydroxyurea, hypericin, ibandronic acid, idarubicin, idarubicin hydrochloride, idoxifene, idramantone, ifosfamide, ihnofosine, ilomastat, imidazoacridones, imiquimod, immunostimulant peptides, insulin-like growth factor-1 receptor inhibitor, interferon agonists, interferon alpha-2A, interferon alpha-2B, interferon alpha-NI, interferon alpha-N3, interferon beta-IA, interferon gamma-IB, interferons, interleukins, iobenguane, iododoxorubicin, iproplatm, irinotecan, irinotecan hydrochloride, iroplact, irsogladine, isobengazole, isohomohalicondrin B, itasetron, jasplakinolide, kahalalide F, lamellarin-N triacetate, lanreotide, lanreotide acetate, leinamycin, lenograstim, lentinan sulfate, leptolstatin, letrozole, leukemia inhibiting factor, leukocyte alpha interferon, leuprolide acetate, leuprolide/estrogen/progesterone, leuprorelin, levamisole, liarozole, liarozole hydrochloride, linear polyamine analog, lipophilic disaccharide peptide, lipophilic platinum compounds, lissoclinamide, lobaplatin, lombricine, lometrexol, lometrexol sodium, lomustine, lonidamine, losoxantrone, losoxantrone hydrochloride, lovastatin, loxoribine, lurtotecan, lutetium texaphyrin lysofylline, lytic peptides, maitansine, mannostatin A, marimastat, masoprocol, maspin, matrilysin inhibitors, matrix metalloproteinase inhibitors, maytansine, mechlorethamine hydrochloride, megestrol acetate, melengestrol acetate, melphalan, menogaril, merbarone, mercaptopurine, meterelin, methioninase, methotrexate, methotrexate sodium, metoclopramide, metoprine, meturedepa, microalgal protein kinase C uihibitors, MIF inhibitor, mifepristone, miltefosine, mirimostim, mismatched double stranded RNA, mitindomide, mitocarcin, mitocromin, mitogillin, mitoguazone, mitolactol, mitomalcin, mitomycin, mitomycin analogs, mitonafide, mitosper, mitotane, mitotoxin fibroblast growth factor-saporin, mitoxantrone, mitoxantrone hydrochloride, mofarotene, molgramostim, monoclonal antibody, human chorionic gonadotrophin, monophosphoryl lipid a/myobacterium cell wall SK, mopidamol, multiple drug resistance gene inhibitor, mustard anticancer agent,

mycaperoxide B, mycobacterial cell wall extract, mycophenolic acid, myriaporone, n-acetyldinaline, nafarelin, nagrestip, naloxone/pentazocine, napavin, naphterpin, nartograstim, nedaplatin, nemorubicin, neridronic acid, neutral endopeptidase, nilutamide, nisamycin, nitric oxide modulators, nitroxide antioxidant, nitrullyn, nocodazole, nogalamycin, n-substituted benzamides, O6-benzylguanine, octreotide, okicenone, oligonucleotides, onapristone, ondansetron, oracin, oral cytokine inducer, ormaplatin, osaterone, oxaliplatin, oxaunomycin, oxisuran, paclitaxel, paclitaxel analogs, paclitaxel derivatives, palauamine, palmitoylrhizoxin, pamidronic acid, panaxytriol, panomifene, parabactin, pazelliptine, pegaspargase, peldesine, peliomycin, pentamustine, pentosan polysulfate sodium, pentostatin, pentrozole, peplomycin sulfate, perflubron, perfosfamide, perillyl alcohol, phenazinomycin, phenylacetate, phosphatase inhibitors, picibanil, pilocarpine hydrochloride, pipobroman, piposulfan, pirarubicin, piritrexim, piroxantrone hydrochloride, placetin A, placetin B, plasminogen activator inhibitor, platinum complex, platinum compounds, platinum-triamine complex, plicamycin, plomestane, porfimer sodium, porfiromycin, prednimustine, procarbazine hydrochloride, propyl bis-acridone, prostaglandin J2, prostatic carcinoma antiandrogen, proteasome inhibitors, protein A-based immune modulator, protein kinase C inhibitor, protein tyrosine phosphatase inhibitors, purine nucleoside phosphorylase inhibitors, puromycin, puromycin hydrochloride, purpurins, pyrazorurin, pyrazoloacridine, pyridoxylated hemoglobin polyoxyethylene conjugate, RAF antagonists, raltitrexed, ramosetron, RAS farnesyl protein transferase inhibitors, RAS inhibitors, RAS-GAP inhibitor, retelliptine demethylated, rhenium RE 186 etidronate, rhizoxin, riboprine, ribozymes, RH retinarnide, RNAi, rogletimide, rohitukine, romurtide, roquinimex, rubiginone B1, ruboxyl, safingol, safingol hydrochloride, saintopin, sarcnu, sarcophytol A, sargramostim, SDI1 mimetics, semustine, senescence derived inhibitor 1, sense oligonucleotides, signal transduction inhibitors, signal transduction modulators, simtrazene, single chain antigen binding protein, sizofiran, sobuzoxane, sodium borocaptate, sodium phenylacetate, solverol, somatomedin binding protein, sonermin, sparfosafe sodium, sparfosic acid, sparsomycin, spicamycin D, spirogermanium hydrochloride, spiromustine, spiroplatin, splenopentin, spongistatin 1, squalamine, stem cell inhibitor, stem-cell division inhibitors, stipiamide, streptonigrin, streptozocin, stromelysin inhibitors, sulfinosine, sulofenur, superactive vasoactive intestinal peptide antagonist, suradista, suramin, swainsonine, synthetic glycosaminoglycans, talisomycin, tallimustine, tamoxifen methiodide, tauromustine, tazarotene, tecogalan sodium, tegafur, tellurapyrylium, telomerase inhibitors, teloxantrone hydrochloride, temoporfin, temozolomide, teniposide, teroxirone, testolactone, tetrachlorodecaoxide, tetrazomine, thaliblastine, thalidomide, thiamiprine, thiocoraline, thioguanine, thiotepa, thrombopoietin, thrombopoietin mimetic, thymalfasin, thymopoietin receptor agonist, thymotrinan, thyroid stimulating hormone, tiazofurin, tin ethyl etiopurpurin, tirapazamine, titanocene dichloride, topotecan hydrochloride, topsentin, toremifene, toremifene citrate, totipotent stem cell factor, translation inhibitors, trestolone acetate, tretinoin, triacetyluridine, triciribine, triciribine phosphate, trimetrexate, trimetrexate glucuronate, triptorelin, tropisetron, tubulozole hydrochloride, turosteride, tyrosine kinase inhibitors, tyrphostins, UBC inhibitors, ubenimex, uracil mustard, uredepa, urogenital sinus-derived growth inhibitory factor, urokinase receptor antagonists, vapreotide, variolin B, velaresol, veramine, verdins, verteporfin, vinblastine sulfate, vincristine sulfate, vindesine, vindesine sulfate, vinepidine sulfate, vinglycinate sulfate, vinleurosine sulfate, vinorelbine, vinorelbine tartrate, vinrosidine sulfate, vinxaltine, vinzolidine sulfate, vitaxin, vorozole, zanoterone, zeniplatin, zilascorb, zinostatin, zinostatin stimalamer, or zorubicin hydrochloride, siRNA or any combinations thereof;

18. The method according of embodiment 1-17, wherein said at least one targeting agent is selected from antibodies, PMSA ligands and polypeptides that bind to epidermal growth factor receptor (EGFR), somatostatin receptor (SSTR), insulin-like growth factor receptor, folic acid-receptor, HER2 receptor, interleukin-13 receptor, gastrin-releasing peptide receptor, CD30, vasoactive intestinal peptide receptor, gastrin receptor, prostate-specific antigen, and/or the estrogen receptor;

19. The method of embodiment 1-18, wherein said method is performed in an aqueous medium;

20. The method of embodiment 1-18, wherein said method is performed in an organic solvent;

21. A nanoparticle produced according to the methods of embodiments 1-20;

22. A composition comprising the nanoparticle of embodiment 21 and a pharmaceutically acceptable carrier;

23. A method of treating a disease comprising the administration of a nanoparticle according of embodiment 21 to a subject in an amount sufficient to treat said disease;

24. The method of embodiment 23, wherein said disease is selected from lung cancer, breast cancer, prostate cancer, head and neck cancer, ovarian cancer, skin cancer, testicular cancer, pancreatic cancer, esophageal cancer, colorectal cancer, kidney cancer, cervical cancer, gastrointestinal cancer, viral infections, bacterial infections or

inflammation; and

25. A polymer produced according to the method of embodiments 1-19, said polymer comprising a targeting agent covalently bound to the α terminus of a poly(ethylene glycol) polymer and at least one second polymer covalently bound to said poly(ethylene glycol) polymer via a functional group present on the ω terminus of said poly(ethylene glycol).

[0069] It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application, in as far as covered by the present claims. In addition, any elements or limitations of any invention or embodiment thereof disclosed herein can be combined with any and/or all other elements or limitations (individually or in any combination) or any other invention or embodiment thereof disclosed herein, in as far as they are covered by the present claims.

Example 1. Synthesis of HO-PEG-lys-urea-glu(protected) by covalent conjugation of lys-urea-glu (protected) to HO-PEG-CO_2H

[0070] Materials used for the synthesis and purification of HO-PEG-lys-urea-glu(protected) included α-hydroxyethyl-ω-carboxypentyl, poly(ethylene glycol) (Average Molecular Weight = 5 Kg/mol, Terminal Activity = 98%) (HO-PEG-CO_2H, NOF America Corporation, White Plains, New York); Diprop-2-en-1-yl *N*-{[6-ammonio-1-oxo-1-(prop-2-en-1-yloxy)hexan-2-yl]carbamoyl}glutamate trifluoroacetate (lys-urea-glu(protected), Organix, Woburn, MA); N-(3-dimethylaminopropyl)-N'-ethyl carbodiimide (≥97.0%) (EDC, Sigma-Aldrich); N-Ethyl Di-isopropyamine (99.5%) (DIEA, Sigma-Aldrich); N-hydroxysuccinimide (98%) (NHS, Sigma-Aldrich); Chloroform (Anhydrous, ≥99%) Sigma-Aldrich); Ethanol (Absolute, ≥99.5%) (Sigma-Aldrich).

[0071] Instrumentation used for the in-process characterization and work-up of HO-PEG-lys-urea-glu(protected) included Bruker 400 MHz Nuclear Magnetic Resonance Spectrometer for Proton NMR Spectroscopic Analysis; Vacuum atmospheres dry nitrogen glove box (< 1ppm water); Edwards RV5 Vacuum Pump and a VWR Oven for Vacuum Drying; Ultrafiltration Diafiltration (UFDF) System based on a peristaltic pump (Masterson), Regenerated Cellulose Membrane filter (Millipore, Surface area = 0.1 m^2, MWCO 3 kDa), and expanded PTFE tubing (Chem-Sure); Rotary Evaporator (Buchi); Millipore 2L Vacuum Filtration Assembly and Millipore 0.2 um Fluoropore (PTFE) Membrane Filters;Waters Size Exclusion Chromatography system equipped with Refractive Index Detector and Waters HR1, HR3 and HR4 columns (7.8 X 300 mm, Molecular Weight Range 100 - 5000 Da, 500 - 30,000 Da, 5000 - 600,000 Da, respectively). Number and Weight Average Molar Mass was determined using Poly(ethylene glycol) calibration standards from Shodex Standards, (Kawasaki, Japan) of Peak Molar Mass (Mp = 960, 1400, 4290, 7130, 12900, 20600 Da).

[0072] Experimental procedure: All reagents (HO-PEG-CO_2H, lys-urea-glu(protected), EDC, NHS, DIEA and anhydrous chloroform) were transferred to a dry nitrogen glove box and subsequently weighed or transferred (using volumetric pipettes or microliter syringes) in 20 mL reaction vials under argon at room temperature. NHS (230 mg, 2 mmol) was added to a solution of HO-PEG-CO_2H (1 g, 0.2 mmol) in anhydrous chloroform (5 mL) (solution A). GL2P (1.106 g, 2 mmol) was dissolved in anhydrous chloroform (5 mL), then EDC (354 uL, 2mmol) and DIEA (685 uL, 4 mmol) were added to this solution (solution B). Solution B was added to solution A and the reaction vial (solution AB) closed under argon. Solution AB was then moved to a vented fume hood and magnetically stirred at room temperature for 2 hours in the dark (reaction vial was wrapped in aluminum foil). Solution AB was diluted with ethanol (100 mL) yielding solvent composition of ethanol/chloroform (10:1) (Solution C). Solution C was diafiltered against 29 dia-volumes (1.5L) of binary solvent mixture of ethanol/chloroform (9:1 by volume) at a flow rate of 800 mL/min and a 30 - 40 psi back pressure applied by appropriately adjusting a ¼ turn ball valve. Under these UFDF conditions, the permeate flow rate is approximately 5 mL/min. Solvent was removed from the retentate solution (solution CR) by rotary evaporation at 35 °C and subsequently vacuum dried at room temperature of 18 hours to obtain crude product (770mg, 70%). Crude product was dissolved in 7.7 mL of chloroform (100 mg/mL, solution D). Solution D was added drop-wise to 150 ml of ether/hexane (70/30) precipitant while stirring. The precipitated product was recovered by filtration using 0.2 micron PTFE membrane filter in a Millipore vacuum filtration apparatus. Purified product, HO-PEG-lys-urea-glu(protected) (white powder, 700 mg, 91%) was obtained by vacuum drying at room temperature for 24 hours to remove residual solvents.

Example 2. Characterization of HO-PEG-lys-urea-glu(protected) to determine the mol% end functionalization with of PEG with lys-urea-glu targeting agent and its molar mass

[0073] Identity of HO-PEG-lys-urea-glu(protected) was ascertained by 1H NMR in D_2O using the following instrument parameters: NMR field strength = 400 MHz; Number of scans = 128; Pulse delay = 5sec; Pulse width = 7μsec. NMR peak assignments are as follows: Allyl sp^2 CH (3H multiplet, 5.9 - 6.03ppm), allyl sp^2 CH_2 (6H, two overlapping doublets,

5.27 - 5.4ppm), allyl sp^3 CH_2 (6H, two overlapping doublets, 4.6 - 4.7ppm), PEG terminal CH_2-OH (2H triplet, 3.85 - 3.92ppm), PEG ethylene oxide CH_2 (ca. 408H based on M_n KDa, singlet 3.7ppm), PEG terminal CH_2 epsilon to CONH-lys-urea-glu (2H triplet, 3.5 - 3.55ppm), lysine CH_2 epsilon C (2H two triplets, 3.05 - 3.14ppm and 3.15 - 3.22ppm), PEG terminal CH_2 alpha to CONH-lys-urea-glu and PEG terminal CH_2 alpha to COOH of uncoupled PEG (2H multiplet, 2.15 - 2.3ppm), glutamic acid CH_2 gamma C (two 2H overlapping triplets 2.5 - 2.6ppm), glutamic acid CH_2 beta C (two 1H multiplets, 1.8 - 2.1ppm), lysine CH_2 beta C (1H multiplet, 1.67 - 1.8ppm). The overlapping multiplets between 1.3 and 1.67ppm were assigned to (a) lysine CH_2 beta C (1H), (b) lysine CH_2 gamma C (2H), (c) lysine CH_2 delta C (2H), (d) PEG terminal CH_2's beta and delta to CONH-lys-urea-glu (2H each), (e) PEG terminal CH_2 gamma to CONH-lys-urea-glu (2H). Lys-urea-glu incorporation into HO-PEG-lys-urea-glu(protected) product was estimated using the ratio the ligand multiplet between 1.95 - 2.1ppm and PEG multiplet between 2.15 - 2.3ppm yielding 82% incorporation of lys-urea-glu(protected) into HO-PEG-lys-urea-glu(protected) conjugate.

[0074] See Figure 1 for proton NMR spectra of HO-PEG-lys-urea-glu(protected), lot numbers 11-189-1 and 11-176-1.

[0075] Molecular weight of HO-PEG-lys-urea-glu(protected) was determined by Size Exclusion Chromatography using Refractive Index detection and chloroform as elution solvent. Column Temperature = 30 °C, RI Detector temperature = 35 °C, Sample concentration = 10 mg/mL, Injection volume = 10 uL. Number and Weight Average Molecular Weight (M_n and M_w) were obtained relative to narrow disperse Poly(ethylene glycol) standards from Polymer Standards Service USA (Warwick, Rhode Island). A fourth order polynomial fit (R^2 = 0.99957; Standard Error = 0.02) yielded Mn = 5200 Da; Mw = 5700 Da; Mw/Mn = 1.1 for HO-PEG-lys-urea-glu(protected).

[0076] See Figure 2 for Size Exclusion Chromatograms (SEC) of HO-PEG-lys-urea-glu(protected), lot numbers 11-189-1 (labeled 44-44-6 for SEC analysis) and 11-176-1.

Example 3. Synthesis of PLA-PEG-lys-urea-glu(protected) by ring opening polymerization of D,L-lactide using HO-PEG-lys-urea-glu (protected) as macroinitiator and tin(II) 2-ethylhexanoate as polymerization catalyst

[0077] Materials used in the synthesis of PLA-PEG-lys-urea-glu(protected) included HO-PEG-lys-urea-glu(protected), synthesized as described in Example 1; Tin (II) 2-ethylhexanoate (95%) ($Sn(Oct)_2$, Sigma-Aldrich); D,L-lactide (≥99.5%, Altasorb, Piedmont, SC); Hexane, anhydrous (95% DriSolv, EMD) in polymerization reaction and Hexane (Chromasolv., ≥95%, Sigma) for work-up precipitation; Diethyl ether (≥99.0%, Sigma);

[0078] Instrumentation used for In-process characterization and reaction/work-up of PLA-PEG-lys-urea-glu(protected) included a Bruker 400 MHz Nuclear Magnetic Resonance Spectrometer for Proton NMR Spectroscopic Analysis at Spectral Data Services, Champaign, IL; Vacuum atmospheres dry nitrogen glove box (< 1ppm water); 12-place parallel reaction carusel (Brinkmann-Hiedolph) equipped with a multi-position stir plate and solid state temperature controller (IKA multi-stir plate and temperature controller with feed-back loop; Schlenk reaction tubes equipped with a Teflon stop cock side arm. Edwards RV5 Vacuum Pump and a VWR Oven for Vacuum Drying; Rotary Evaporator (Buchi); Waters Size Exclusion Chromatography system equipped with Refractive Index Detector and Waters HR1, HR3 and HR4 columns (7.8 X 300 mm, Molecular Weight Range 100 - 5000 Da, 500 - 30,000 Da, 5000 - 600,000 Da, respectively). Number and Weight Average Molar Mass was determined using Poly(styrene) calibration standards from Shodex Standards, (Kawasaki, Japan) of Peak Molar Mass (Mp = 1200, 3900, 12800, 31,400, 55,100, and 197,000 Da).

[0079] Experimental procedure: All reagents (HO-PEG-lys-urea-glu(protected), $Sn(Oct)_2$, d,l-lactide, anhydrous hexane) were transferred to a dry argon glove box and subsequently manipulated under dry nitrogen at room temperature. HO-PEG-lys-urea-glu (200mg, 4×10^{-2}mmol) and lactide (800mg, 5.55mmol) were weighed into reaction tube (containing a suitably size magnetic stir bar) and septum sealed under dry argon (mixture A). $Sn(Oct)_2$ (250mg) was weighed into a 6mL glass vial and dissolved in anhydrous hexane (2.5mL) to yield a 100 mg/mL solution (B) and septum sealed under dry nitrogen. Mixture A was removed to a vented fume hood and dried under a steady stream of dry argon for 1 hour at room temperature using argon gas manifold equipped with a 8 inch needles as argon gas inlets. Schlenk reaction tube side arms were connected to a silicone oil bubbler to serve as argon gas outlet. The Schlenk tubes were subsequently sealed by stopping the inlet argon flow from the argon gas manifold and the side arm gas outlet through the schlenk tube side arm using the Teflon stop cork. Sealed Schlenk tubes were placed in a 130 °C silicone oil bath and magnetically stirrer to obtain a clear colorless lactide monomer melt (about 10 minutes). Solution B (80 uL) was introduced via a 500uL syringe via the septum seal. The reaction mixture (C) was allowed to stir at 130 °C for 16 hours. Reaction mixture C was cooled to room temperature, Schlenk tube opened in air and polymer pellet dissolved in 5 mL dichloromethane by vortexing for 1 hour at room temperature (solution D). Solution D was transferred to a 20mL glass vial and Schlenk tube rinsed with 2 X 2.5mL portion of fresh dichloromethane. The washing were combined with solution D. This slightly turbid solution was filtered using 0.45 micron PTFE syringe filters to obtain a clear colorless solution (Solution E). Solution E was added drop-wise to diethyl ether/hexane (70/30) (200 mL) while stirring at room temperature. The cloudy precipitate was allowed to stir at room temperature for 2 hours to allow polymer to coagulate and settle to the bottom of the beaker. The clear supernatant was decanted and the tacky polymer product (700mg, 70%) was transferred to glass vial using spatula and subsequently dried under vacuum at room temperature for 18 hours.

Example 4. Characterization of PLA-PEG-lys-urea-glu(protected) to determine the mol% end functionalization with of PEG with lys-urea-glu targeting agent and its molar mass

[0080] Identity of PLA-PEG-lys-urea-glu(protected) was ascertained by 1H NMR in chloroform-d using the following instrument parameters: NMR field strength = 400 MHz; Number of scans = 128; Pulse delay = 5sec; Pulse width = 7μsec. NMR peak assignments are as follows: Lactide methine CH (1H multiplet, 5.1 - 5.3ppm), Lactide methyl CH_3 (3H multiplet, 1.45 - 1.65), PEG ethylene oxide CH_2 (ca. 408H based on M_n=5 KDa, singlet 3.55 - 3.8), allyl sp^2 CH (3H multiplet, 5.8 - 6.0ppm). The number average molar mass (Mn) of PLA-PEG-lys-urea-glu(protected) was determined by proton NMR spectroscopy using PEG to poly(d,l-lactide) ratio. Comparison of the intensities of the allyl sp^2 CH (3H multiplet, 5.8 - 6.0ppm) peak and the lactide methine CH (1H multiplet, 5.1 - 5.3ppm) peak yielded M_n (PLA-PEG-lys-urea-glu(protected) = 20,100 Da assuming PEG M_n = 5 Kg/mol.

[0081] See Figure 3 for proton NMR spectra of PLA-PEG-lys-urea-glu(protected), lot numbers 11-187-1, 11-188-1 and 11-198-1.

[0082] Molecular weight of PLA-PEG-lys-urea-glu(protected) was also determined by Size Exclusion Chromatography using Refractive Index detection and chloroform as elution solvent. Column Temperature = 30 °C, RI Detector temperature = 35 °C, Sample concentration = 10 mg/mL, Injection volume = 10 uL. M_n and M_w were obtained relative to narrow disperse Polystyrene Standards (Shodex Standards, Kawasaki, Japan). A fourth order polynomial fit (R^2 = 0.999977; Standard Error = 0.009) yielded M_n = 20700 Da; M_w = 25400 Da; Mw/Mn = 1.23 for PLA-PEG-PLA-PEG-lys-urea-glu(protected).

[0083] See Figure 4 for Size Exclusion Chromatograms (SEC) of HO-PEG-lys-urea-glu(protected), lot numbers 11-189-1 (labeled 44-44-6 for SEC analysis) and 11-176-1.

Example 5. Synthesis of PLA-PEG-lys-urea-glu by removal of the allyl protecting groups of PLA-PEG-lys-urea-glu(protected) using tetrakis(triphenylphosphine) palladium (0)

[0084] Materials used for the synthesis of PLA-PEG-lys-urea-glu included PLA-PEG-lys-urea-glu(protected), synthesized as described in example 3;

[0085] Tetrakis(triphenylphosphene)palladium(0)(99%) (Pd-tetrakis, Sigma); Morpholine (99.5%, Sigma); Dichloromethane (Anhydrous, ≥99.8%, Sigma); Diethyl ether (≥99.0%, Sigma); Hexane (Chromasolv., ≥95%, Sigma).

[0086] Instrumentation and equipment used for work-up procedures and in-process characterization included a Bruker 400 MHz Nuclear Magnetic Resonance Spectrometer for Proton NMR Spectroscopic Analysis; Edwards RV5 Vacuum Pump and a VWR Oven for Vacuum Drying; Rotary Evaporator (Buchi).

[0087] Experimental procedure: PLA-PEG-lys-urea-glu(protected) (1000mg, 4.76 X 10^{-2}mmol) was dissolved in anhydrous dichloromethane (4 mL) under ambient air (Solution A). Pd-tetrakis (55mg, 4.76 X 10^{-2}mmol) was dissolved in anhydrous dichloromethane (4 mL) also under ambient air (Solution B). Morpholine (41.5mg or 45.2uL, 0.476 mmol) was added to solution A, this was immediately followed by the addition of Solution B to Solution A. Dichloromethane (2 mL) was used to rinse the Solution B vial and this rinse solution was combined with Solution A to ensure quantitative transfer of the Pd-tetrakis to the reaction mixture (C). Mixture C was allowed to stir closed and in the dark (reaction vial was wrapped in aluminum foil) at room temperature for 2 hours. Reaction mixture C was opened in air and added dropwise into diethyl ether/hexane (70/30, (v/v)) (200 mL) at room temp while stirring. The resulting polymer suspension was allowed to stir at room temperature for 2 hours allowing it to coagulate and settle to the bottom of the beaker. The clear supernatant was decanted off and the tacky polymer was transferred using spatula to a glass vial. PLA-PEG-lys-urea-glu (800mg, 80%) product was dried under vacuum for 18 hours at room temperature.

Example 6. Palladium removal from PLA-PEG-lys-urea-glu using trimercapto triazide functional palladium scavenging resin

[0088] PLA-PEG-lys-urea-glu (1050mg) was dissolved in dichloromethane (30 mL) to yield a 35 mg/mL solution. Palladium scavenging resin (TMT, 5g in 60 mL column) was solvated with dichloromethane (10 mL) and PLA-PEG-lys-urea-glu solution (30 mL) added. Eluant was collected under gravity and column rinsed with additional dichloromethane (40 mL). Main and rinse eluant fractions combined and solvent removed by rotary evaporation to recover polymer. Polymer was subsequently dissolved in dichloromethane (10.5 mL, 100 mg/mL solution) and added dropwise to 70/30 ether/hexane (210 mL). The resulting polymer suspension was allowed to stir at room temperature for 2 hours allowing it to coagulate and settle to the bottom of the beaker. The clear supernatant was decanted off and the tacky PLA-PEG-lys-urea-glu polymer was transferred using spatula to a glass vial (940mg, 90%).

Example 7. Characterization of PLA-PEG-lys-urea-glu to determine the efficiency of deprotection, molar mass and residual palladium content

[0089] The identity of PLA-PEG-lys-urea-glu was ascertained by 1H NMR in chloroform-d using the following instrument parameters: NMR field strength = 400 MHz; Number of scans = 128; Pulse delay = 5sec; Pulse width = 7μsec. NMR peak assignments are as follows: Lactide methine CH (1H multiplet, 5.1 - 5.3ppm), Lactide methyl CH_3 (3H multiplet, 1.45 - 1.7), PEG ethylene oxide CH_2 (ca. 408H based on M_n=5 KDa, singlet 3.55 - 3.8), residual allyl sp^2 CH (3H multiplet, 5.8 - 6.0ppm).

[0090] The efficiency of deprotection reaction was also determined by NMR as 95% (allyl removal). This was calculated using the ratio of the intensity of the residual allyl peak in the product PLA-PEG-lys-urea-glu spectrum to that of the corresponding peak in the starting material (PLA-PEG-lys-urea-glu(protected)) spectrum.

[0091] The number average molar mass (M_n) of PLA-PEG-lys-urea-glu was estimated by NMR using PEG to poly(d,l-lactide) ratio. Comparison of the intensities of the PEG ethylene oxide CH_2 (408H, singlet 3.55 - 3.8) peak and the lactide methine CH (1H multiplet, 5.1 - 5.3ppm) peak yielded M_n (PLA-PEG-lys-urea-glu) = 21,400 Da assuming PEG M_n = 5 Kg/mol.

[0092] Palladium content in product PLA-PEG-lys-urea-glu was determined by ICP Spectrometry and found < 5ppm.

[0093] The molar mass of PLA-PEG-lys-urea-glu was estimated by measurement of inherent viscometry (IV) in dimethylsulfoxide and chloroform (0.309 dL/g and 0.198 dL/g, respectively). The I.V. of the protected precursor PLA-PEG-lys-urea-glu(protected) was determined in dimethylsulfoxide (0.217 dL/g). A minor drop in viscosity from 0.217 dL to 0.198 dL/g was observed and may be attributed to differences in polymer solvent interactions as a result of the more polar nature of lys-urea-glu relative to the allyl protected precursor.

[0094] See Figure 5 for proton NMR spectra of crude (prior to palladium removal) PLA-PEG-lys-urea-glu, lot numbers 11-187-1, 11-188-1 and 11-198-1.

[0095] See Figure 6 for proton NMR spectra of purified (after palladium removal) PLA-PEG-lys-urea-glu, lot number 44-49-1.

[0096] See Figure 7 for Inherent viscosity of purified (after palladium removal) PLA-PEG-lys-urea-glu, lot number 44-49-1 and the protected precursor PLA-PEG-lys-urea-glu(protected)

[0097] See Figure 8 for Palladium Content in crude (prior to palladium removal) PLA-PEG-lys-urea-glu lot number 44-48-1 (sample code 11-204-1) and purified (after palladium removal) PLA-PEG-lys-urea-glu lot number 44-49-1 (sample code 11-204-2) determined by ICP Spectrometry.

Claims

1. A method of preparing a nanoparticle comprising:

   providing a targeting agent (TA);
   protecting functional groups of said targeting agent;
   providing a functionalized poly(ethylene glycol) (PEG) polymer;
   reacting the functionalized poly(ethylene glycol) polymer with the protected targeting agent (PRO-TA) to form a targeting agent-PEG polymer complex;
   conjugating the targeting agent-PEG polymer complex with a second polymer to form a targeting agent-PEG polymer-second polymer complex; and
   mixing the targeting agent-PEG polymer-second polymer complex with a second polymer and a therapeutic agent to form a nanoparticle.

2. The method of claim 1, wherein the poly(ethylene glycol) is hetero-bifunctional and said targeting agent is covalently bound to the α terminus of said poly(ethylene glycol) and at least one polymerization initiating functional group is present on the ω terminus of said poly(ethylene glycol).

3. The method of claim 2, wherein said at least one polymerization initiating functional group is a hydroxyl (-OH) group or an amine ($-NH_2$) group at the free ω terminus that reacts with a second copolymer.

4. The method of claim 3, wherein the second polymer comprises a blend of two or more polymers and contains at least one functional group that reacts the functional group present at the free ω terminus of said poly(ethylene glycol) and said at least one functional group of said blend of two or more polymers is a hydroxyl group, a NHS group or an amine group.

5. The method of claim 1, wherein the second polymer or the copolymer is a polyester copolymer that contains at least one functional group selected from a hydroxyl group, a NHS group or an amine group and that reacts the functional group present at the free ω terminus of said poly(ethylene glycol).

6. The method of claim 4, wherein the second polymer or the copolymer is a polyester copolymer that contains at least one functional group selected from a hydroxyl group, a NHS group or an amine group and that reacts the functional group present at the free ω terminus of said poly(ethylene glycol).

7. The method of claim 6, wherein said polyester copolymer comprises a heteropolymer or a homopolymer.

8. The method of claim 7, wherein said heteropolymer comprises lactic acid and glycolic acid units or poly(lactic acid-co-glycolic acid) and poly(lactide-co-glycolide) units (PLGA); and said homopolymer comprises glycolic acid units (PGA), lactic acid units (PLA), poly-L-lactic acid units, poly-D-lactic acid units, poly-D,L-lactic acid units, poly-L-lactide units, poly-D-lactide units or poly-D,L-lactide units.

9. The method of claim 6, wherein said polyester copolymer is selected from polyhydroxyacids; PEGylated polymers and copolymers of lactide units and glycolide units, PEGylated PLA, PEGylated PGA, PEGylated PLGA, polyanhydrides, poly(ortho ester) PEGylated poly(ortho ester), poly(caprolactone), PEGylated poly(caprolactone), polylysine, PEGylated polylysine, poly(ethylene inline), PEGylated poly(ethylene imine), poly(L-lactide-co-L-lysine), poly(serine ester), poly(4-hydroxy-L-proline ester), poly[a-(4-aminobutyl)-L-glycolic acid] or derivatives thereof.

10. The method of claim 1, wherein the functional group on the targeting agent is a free carboxylic acid group or a free hydroxyl group and the free carboxylic acid group or the free hydroxyl group is protected prior to reacting the functionalized poly(ethylene glycol) polymer with the targeting agent to form a targeting agent-PEG polymer complex.

11. The method of claim 4, wherein said functional group of said second polymer is:

a) an amine group that reacts with a hydroxyl group or carboxylic acid group on said targeting agent-PEG complex; or
b) a hydroxyl group or an NHS group that reacts with an amine group on said targeting agent-PEG complex.

12. The method of claim 6, wherein said functional group of said second polymer or said copolymer is:

a) an amine group that reacts with a hydroxyl group or carboxylic acid group on said targeting agent-PEG complex; or
b) a NHS or hydroxyl group that reacts with an amine group on said targeting agent-PEG complex.

13. The method of claim 1, wherein said second polymer is a blend of at least two polymers which can be the same or different polymer, wherein the first of said at least two polymers contains at least one hydroxyl group or an NHS group as a functional group and the second of said at least two polymers contains at least one amine group as said functional group.

14. The method of claim 1, wherein said therapeutic agent is an antibiotic, anti-cancer agent, antiviral agent, anti-inflammatory agent a diagnostic agent, a vaccine antigen or a nutraceutical.

15. The method of claim 1, wherein said at least one targeting agent is selected from antibodies, prostate specific membrane antigen (PMSA) ligands and polypeptides that bind to epidermal growth factor receptor (EGFR), somatostatin receptor (SSTR), insulin-like growth factor receptor, folic acid-receptor, HER2 receptor, interleukin-13 receptor, gastrin-releasing peptide receptor, CD30, vasoactive intestinal peptide receptor, gastrin receptor, prostate-specific antigen, and/or the estrogen receptor.

16. The method of claim 1, wherein said method is performed in an aqueous medium or in an organic solvent.

Patentansprüche

1. Verfahren zur Herstellung eines Nanopartikels, umfassend:

Bereitstellen eines Targeting-Mittels (TM);
Schützen funktioneller Gruppen des Targeting-Mittels;
Bereitstellen eines funktionalisierten Poly(ethylenglycol) (PEG)-Polymers;
Umsetzen des funktionalisierten Poly(ethylenglycol) (PEG)-Polymers mit dem geschützten Targeting-Mittel (PRO-TM), um einen Targeting-Mittel-PEG-Polymer-Komplex zu bilden;
Konjugieren des Targeting-Mittel-PEG-Polymer-Komplexes mit einem zweiten Polymer, um einen Targeting-Mittel-PEG-Polymer-zweites-Polymer-Komplex zu bilden; und
Mischen des Targeting-Mittel-PEG-Polymer-zweites-Polymer-Komplexes mit einem zweiten Polymer und einem therapeutischen Mittel, um einen Nanopartikel zu bilden.

2. Verfahren gemäß Anspruch 1, wobei das Poly(ethylenglycol) hetero-bifunktionell ist und das Targeting-Mittel kovalent an den α-Terminus des Poly(ethylenglycol) gebunden ist und mindestens eine polymerisationinitiierende funktionelle Gruppe an dem ω-Terminus des Poly(ethylenglycol) vorhanden ist.

3. Verfahren gemäß Anspruch 2, wobei die mindestens eine polymerisationinitiierende funktionelle Gruppe eine Hydroxyl (-OH)-Gruppe oder eine Amin ($-NH_2$)-Gruppe an dem freien ω-Terminus ist, welche mit einem zweiten Copolymer reagiert.

4. Verfahren gemäß Anspruch 3, wobei das zweite Polymer eine Mischung aus zwei oder mehr Polymeren umfasst und mindestens eine funktionelle Gruppe enthält, welche die funktionelle Gruppe, die an dem freien ω-Terminus des Poly(ethylenglycol) vorhanden ist, umsetzt, und die mindestens eine funktionelle Gruppe der Mischung aus zwei oder mehr Polymeren eine Hydroxylgruppe, eine NHS-Gruppe, oder ein Amingruppe ist.

5. Verfahren gemäß Anspruch 1, wobei das zweite Polymer oder das Copolymer ein Polyestercopolymer ist, welches mindestens eine funktionelle Gruppe, ausgewählt aus einer Hydroxylgruppe, einer NHS-Gruppe oder einer Amingruppe enthält und, welches die funktionelle Gruppe, welche an dem freien ω-Terminus des Poly(ethylenglycol) vorhanden ist, umsetzt.

6. Verfahren gemäß Anspruch 4, wobei das zweite Polymer oder das Copolymer ein Polyestercopolymer ist, welches mindestens eine funktionelle Gruppe, ausgewählt aus einer Hydroxylgruppe, einer NHS-Gruppe oder einer Amingruppe enthält und, welches die funktionelle Gruppe, welche an dem freien ω-Terminus des Poly(ethylenglycol) vorhanden ist, umsetzt.

7. Verfahren gemäß Anspruch 6, wobei das Polyestercopolymer ein Heteropolymer oder ein Homopolymer umfasst.

8. Verfahren gemäß Anspruch 7, wobei das Heteropolymer Milchsäure- und Glycolsäureeinheiten oder Poly(milchsäure-co-glycolsäure)- und Poly(lactid-co-glycolid)-Einheiten (PLGA) umfasst; und das Homopolymer Glycolsäureeinheiten (PGA), Milchsäureeinheiten (PLA), Poly-L-milchsäureeinheiten, Poly-D-milchsäureeinheiten, Poly-D,L-milchsäureeinheiten, Poly-L-lactideinheiten, Poly-D-lactideinheiten oder Poly-D,L-lactideinheiten umfasst.

9. Verfahren gemäß Anspruch 6, wobei das Polyestercopolymer aus Polyhydroxysäuren; PEGyliertem Polymeren und Copolymeren der Lactideinheiten und Glycolideinheiten, PEGyliertem PLA, PEGyliertem PGA, PEGyliertem PLGA, Polyanhydriden, Poly(orthoeester), PEGyliertem Poly(orthoester), Poly(caprolacton), PEGyliertem Poly(caprolacton), Polylysin, PEGyliertem Polylysin, Poly(ethyleninline), PEGyliertem Poly(ethylenimin), Poly(L-lactid-co-L-lysin), Poly(serinester), Poly(4-hydroxy-L-prolinester), Poly[a-(4-aminobutyl)-L-glycolsäure] oder Derivaten davon ausgewählt wird.

10. Verfahren gemäß Anspruch 1, wobei die funktionelle Gruppe an dem Targeting-Mittel eine freie Carbonsäuregruppe oder eine freie Hydroxylgruppe ist und die freie Carbonsäuregruppe oder die freie Hydroxylgruppe vor dem Umsetzen des funktionalisierten Poly(ethylenglycol)-Polymers mit dem Targeting-Mittel, um einen Targeting-Mittel-PEG-Polymer-Komplex zu bilden, geschützt wird.

11. Verfahren gemäß Anspruch 4, wobei die funktionelle Gruppe des zweiten Polymers

a) eine Amingruppe, welche mit einer Hydroxylgruppe oder einer Carbonsäuregruppe an dem Targeting-Mittel-PEG-Komplex reagiert; oder
b) eine Hydroxylgruppe oder eine NHS-Gruppe, welche mit einer Amingruppe an dem Targeting-Mittel-PEG-Komplex reagiert, ist.

12. Verfahren gemäß Anspruch 6, wobei die funktionelle Gruppe des zweiten Polymers oder der Copolymers

a) eine Amingruppe, welche mit einer Hydroxylgruppe oder einer Carbonsäuregruppe an dem Targeting-Mittel-PEG-Komplex reagiert; oder
b) eine NHS- oder eine Hydroxylgruppe, welche mit einer Amingruppe an dem Targeting-Mittel-PEG-Komplex reagiert, ist.

13. Verfahren gemäß Anspruch 1, wobei das zweite Polymer eine Mischung aus mindestens zwei Polymeren ist, welche die gleichen oder andere Polymere sein können, wobei das erste der mindestens zwei Polymere mindestens eine Hydroxylgruppe oder eine NHS-Gruppe als eine funktionelle Gruppe enthält, und das zweite der mindestens zwei Polymere mindestens eine Amingruppe als die funktionelle Gruppe enthält.

14. Verfahren gemäß Anspruch 1, wobei das therapeutische Mittel ein Antibiotikum, Anti-Krebs-Mittel, antivirales Mittel, entzündungshemmendes Mittel, ein diagnostisches Mittel, ein Impfstoffantigen oder ein Nutraceuticum ist.

15. Verfahren gemäß Anspruch 1, wobei das mindestens eine Targeting-Mittel aus Antikörpern, Prostata-spezifisches-Memmbran-Antigen (PSMA)-Liganden und Polypeptiden, welche an epidermalen Wachstumsfaktor-Rezeptor (EGFR), Somatostatin-Rezeptor (SSTR), Insulin-ähnlichen Wachstumsfaktor-Rezeptor, Folsäure-Rezeptor, HER2-Rezeptor, Interleukin-13-Rezeptor, Gastrin-freisetzenden Peptid-Rezeptor, CD30, vasoaktiven intestinalen Peptid-Rezeptor, Gastrin-Rezeptor, Prostata-spezifischen Antigen und/oder dem Östrogen-Rezeptor binden, ausgewählt ist.

16. Verfahren gemäß Anspruch 1, wobei das Verfahren in einem wässrigen Medium oder in einem organischen Lösungsmittel durchgeführt wird.

Revendications

1. Procédé de préparation d'une nanoparticule comprenant :

la fourniture d'un agent de ciblage (TA) ;
la protection des groupes fonctionnels dudit agent de ciblage ;
la fourniture d'un polymère de poly(éthylène glycol) (PEG) fonctionnalisé ;
la réaction du polymère de poly(éthylène glycol) fonctionnalisé avec l'agent de ciblage protégé (PRO-TA) pour former un complexe agent de ciblage-polymère de PEG ;
la conjugaison du complexe agent de ciblage-polymère de PEG avec un second polymère pour former un complexe agent de ciblage-polymère de PEG-second polymère ; et
le mélange du complexe agent de ciblage-polymère de PEG-second polymère avec un second polymère et un agent thérapeutique pour former une nanoparticule.

2. Procédé selon la revendication 1, dans lequel le poly(éthylène glycol) est hétéro-bifonctionnel et ledit agent de ciblage est lié par liaison covalente à l'extrémité α dudit poly(éthylène glycol) et au moins un groupe fonctionnel initiant une polymérisation est présent sur l'extrémité ω dudit poly(éthylène glycol).

3. Procédé selon la revendication 2, dans lequel ledit au moins un groupe fonctionnel initiant une polymérisation est un groupe hydroxyle (-OH) ou un groupe amine ($-NH_2$) à l'extrémité ω libre qui réagit avec un second copolymère.

4. Procédé selon la revendication 3, dans lequel le second polymère comprend un mélange de deux ou plus de deux polymères et contient au moins un groupe fonctionnel qui réagit avec le groupe fonctionnel présent à l'extrémité ω libre dudit poly(éthylène glycol) et ledit au moins un groupe fonctionnel dudit mélange de deux ou plus de deux polymères est un groupe hydroxyle, un groupe NHS ou un groupe amine.

5. Procédé selon la revendication 1, dans lequel le second polymère ou le copolymère est un copolymère de polyester qui contient au moins un groupe fonctionnel choisi parmi un groupe hydroxyle, un groupe NHS ou un groupe amine et qui réagit avec le groupe fonctionnel présent à l'extrémité ω libre dudit poly(éthylène glycol).

6. Procédé selon la revendication 4, dans lequel le second polymère ou le copolymère est un copolymère de polyester qui contient au moins un groupe fonctionnel choisi parmi un groupe hydroxyle, un groupe NHS ou un groupe amine et qui réagit avec le groupe fonctionnel présent à l'extrémité ω libre dudit poly(éthylène glycol).

7. Procédé selon la revendication 6, dans lequel ledit copolymère de polyester comprend un hétéro-polymère ou un homopolymère.

8. Procédé selon la revendication 7, dans lequel ledit hétéropolymère comprend des motifs d'acide lactique et d'acide glycolique ou des motifs de poly(acide lactique-co-acide glycolique) et de poly(lactide-co-glycolide) (PLGA) ; et ledit homo-polymère comprend des motifs d'acide glycolique (PGA), des motifs d'acide lactique (PLA), des motifs de polyacide lactique L, des motifs de polyacide lactique D, des motifs de polyacide lactique D,L, des motifs de poly-L-lactide, des motifs de poly-D-lactide ou des motifs de poly-D,L-lactide.

9. Procédé selon la revendication 6, dans lequel ledit copolymère de polyester est choisi parmi les polyhydroxyacides ; les polymères et copolymère pégylés composés de motifs lactide et de motifs glycolide, un PLA pégylé, un PGA pégylé, un PLGA pégylé, les polyanhydrides, un poly(ortho ester), un poly(ortho ester) pégylé, une poly(caprolactone), une poly(caprolactone) pégylée, une polylysine, une polylysine pégylée, une poly(éthylène inline), un poly(éthylène imine) pégylée, un poly(L-lactide-co-L-lysine), un poly(ester de sérine), un poly(ester de 4-hydroxy-L-proline), un poly[acide a-(4-aminobutyl)-L-glycolique] ou leurs dérivés.

10. Procédé selon la revendication 1, dans lequel le groupe fonctionnel sur l'agent de ciblage est un groupe acide carboxylique libre ou un groupe hydroxyle libre et le groupe acide carboxylique libre ou le groupe hydroxyle libre est protégé avant la réaction du polymère de poly(éthylène glycol) fonctionnalisé avec l'agent de ciblage pour former un complexe agent de ciblage-polymère de PEG.

11. Procédé selon la revendication 4, dans lequel ledit groupe fonctionnel dudit second polymère est :

a) un groupe amine qui réagit avec un groupe hydroxyle ou un groupe acide carboxylique sur ledit complexe agent de ciblage-PEG ; ou
b) un groupe hydroxyle ou un groupe NHS qui réagit avec un groupe amine sur ledit complexe agent de ciblage-PEG.

12. Procédé selon la revendication 6, dans lequel ledit groupe fonctionnel dudit second polymère ou dudit copolymère est :

a) un groupe amine qui réagit avec un groupe hydroxyle ou un groupe acide carboxylique sur ledit complexe agent de ciblage-PEG ; ou
b) un groupe NHS ou hydroxyle qui réagit avec un groupe amine sur ledit complexe agent de ciblage-PEG.

13. Procédé selon la revendication 1, dans lequel ledit second polymère est un mélange d'au moins deux polymères qui peuvent être des polymères identiques ou différents, dans lequel le premier desdits au moins deux polymères contient au moins un groupe hydroxyle ou un groupe NHS en tant que groupe fonctionnel et le second desdits au moins deux polymères contient au moins un groupe amine en tant que groupe fonctionnel.

14. Procédé selon la revendication 1, dans lequel ledit agent thérapeutique est un antibiotique, un agent anticancéreux, un agent antiviral, un agent anti-inflammatoire, un agent de diagnostic, un antigène vaccinal ou un nutraceutique.

15. Procédé selon la revendication 1, dans lequel ledit au moins un agent de ciblage est choisi parmi les anticorps, les ligands de l'antigène membranaire spécifique de la prostate (PMSA) et les polypeptides qui se lient au récepteur du facteur de croissance épidermique (EGFR), le récepteur de la somatostatine (SSTR), le récepteur du facteur de croissance insulino-mimétique, le récepteur de l'acide folique, le récepteur HER2, le récepteur de l'interleukine 13, le récepteur du peptide de libération de la gastrine, CD30, le récepteur du peptide intestinal vasoactif, le récepteur de la gastrine, l'antigène spécifique de la prostate, et/ou le récepteur des oestrogènes.

16. Procédé selon la revendication 1, dans lequel ledit procédé est réalisé dans un milieu aqueux ou dans un solvant organique.

FIG. 1A




Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 23688 935647 0.10 986.55 2.269
2 23634 1974K 0.22 899.29 2.250
3 23669 1361K 0.13 891.79 2.232
4 23684 736824 0.08 888.55 2.224
5 24767 935512 0.10 656.47 1.643
6 24799 1636K 0.18 649.62 1.626
7 24832 1665K 0.18 642.54 1.608
8 24863 1078K 0.12 635.98 1.591
9 24918 694237 0.08 624.11 1.562
10 24951 1892K 0.21 617.84 1.544
11 24985 1808K 0.11 609.75 1.526
12 25191 837735 0.09 565.60 1.415
13 25282 844218 0.09 563.25 1.409
14 25222 932727 0.10 558.96 1.399
15 25239 953486 0.11 555.32 1.390
16 25278 1843K 0.21 546.96 1.369
17 25313 1071K 0.12 539.46 1.350
2776.76
10845.75
3754.73
3377.43
4776.08
4655.05
4778.99
2.2
2.0
1.8
1.6
1.4
1.2
PPM

FIG. 1B


Non-Interpolated Peak Listing
#PEAK POINT WEIGHT REL. HT HZ PPM
1 28549 12598K 0.14 3568.46 3.905
2 28589 17898K 0.20 3556.17 3.894
3 28588 16238K 0.18 3550.10 3.884
4 28617 319671 0.04 3545.89 3.868
5 28641 327932 0.04 3538.74 3.855
6 28659 319834 0.04 3536.88 3.846
7 28748 16254K 0.18 3517.83 3.798
8 28755 16866K 0.18 3516.31 3.794
9 28767 15855K 0.18 3513.74 3.788
10 28803 16531K 0.19 3506.82 3.769
11 28898 9846234K 99.99 3485.66 3.718
12 28986 47881K 0.53 3466.80 3.670
13 21897 2678K 0.30 3462.30 3.659
14 21979 578073 0.06 3446.87 3.621
15 21112 405348 0.04 3439.80 3.603
16 21178 1243K 0.14 3425.65 3.567
17 21211 3274K 0.36 3418.58 3.550
18 21238 2759K 0.30 3412.80 3.535
19 21485 279625 0.03 3377.80 3.446
20 21435 820326 0.09 3370.57 3.430
21 21456 1805K 0.11 3363.93 3.413
22 21495 458398 0.05 3357.72 3.397
23 21842 859652 0.10 3283.35 3.231
24 21873 1756K 0.20 3276.70 3.195
25 21904 897190 0.10 3270.86 3.178
26 22010 323238 0.04 3246.93 3.120
27 22042 675321 0.07 3240.48 3.104
28 22073 340823 0.04 3233.84 3.087
29 22867 396939 0.04 3063.67 2.662
30 22881 319489 0.04 3058.67 2.654
31 22911 580782 0.06 3054.24 2.638
32 22936 636579 0.07 3048.89 2.625
33 23964 806841 0.09 3042.89 2.610
34 23038 1165K 0.13 3033.83 2.585
35 23043 2593K 0.29 3025.95 2.567
36 23077 1484K 0.16 3018.67 2.549
3330378.39
12662.33
8284.05
8282.06
22612.09
4.0
3.8
3.6
3.4
3.2
3.0
2.8
2.6
PPM



Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 16593 551876 0.06 2488.29 6.826
2 16618 1313K 0.12 2486.94 6.813
3 16642 1145K 0.13 2397.79 6.888
4 16668 1717K 0.19 2392.22 5.986
5 16694 1657K 0.18 2386.65 5.972
6 16723 1332K 0.15 2380.43 5.957
7 16748 1411K 0.16 2375.87 5.943
8 16773 7015984 0.85 2368.72 5.938
9 17788 2598K 0.29 2153.90 5.398
10 17851 2285K 0.25 2136.54 5.346
11 17983 2723K 0.30 2127.54 5.324
12 17951 3519K 0.38 2117.84 5.298
13 17958 2433K 0.27 2115.75 5.294
14 18911 715568K 8.02 1911.51 4.783
15 18934 902557K 9.96 1910.87 4.782
16 19085 45932K 0.51 1874.22 4.690
17 19110 4623K 0.51 1868.86 4.677
18 19156 3479K 0.27 1859.00 4.652
19 19163 2628K 0.29 1857.93 4.649
20 19182 2449K 0.27 1853.43 4.638
21 19187 25466K 0.28 1852.36 4.635
22 19787 732369 0.08 1740.91 4.356
23 19791 850033 0.09 1735.77 4.343
24 19749 862928 0.10 1731.91 4.334
25 19774 793732 0.09 1726.55 4.320
26 19813 999439 0.11 1718.20 4.300
27 19868 671323 0.07 1706.41 4.270
28 19893 767370 0.08 1701.05 4.257
29 19987 805149 0.09 1698.05 4.249
30 19932 666755 0.07 1692.69 4.236
31 20167 2841G 0.03 1642.33 4.110
32 20197 226958 0.03 1635.98 4.094
1000.00
4952.63
4446.04
3736.60
2758.60
527.11
6.0
5.5
5.0
4.5
PPM

FIG. 1C

GPC Results

	SampleName	Mn	Mw	MP	Mz	Mz+1	Polydispersity	Area (μV*sec)
1	11-176-1	5650	6254	6207	7886	12855	1.106953	900755
2	11-176-1	6150	6992	6530	10624	25873	1.136821	896309




FIG. 2A

GPC Results

	SampleName	Mn	Mw	MP	Mz	Mz+1	Poly dispersity	Area (μV*sec)
1	44-44-6	5744	6987	5561	21172	124257	1.216394	2481892
2	44-44-6	5772	8347	5570	151210	1125097	1.445918	2499828




FIG. 2B

FIG. 3A



Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 16586 242421 0.89 2357.87 5.858
2 17595 255058 0.88 2140.83 5.357
3 17681 257295 0.89 2139.54 5.354
4 17617 221437 0.88 2136.11 5.345
5 17782 834634 0.29 2117.90 5.300
6 17725 240624 0.88 2112.97 5.287
7 17731 256148 0.89 2111.68 5.284
8 17756 381622 0.13 2106.32 5.271
9 17762 385232 0.14 2105.04 5.268
10 17768 311542 0.11 2103.75 5.264
11 17774 346648 0.12 2102.47 5.261
12 17780 378456 0.13 2101.18 5.258
13 17794 14438 0.51 2098.18 5.250
14 17804 10388 0.36 2096.04 5.245
15 17816 45087 1.76 2091.32 5.233
16 17858 60356 2.12 2084.46 5.216
17 17885 58366 2.05 2078.68 5.202
18 17918 75288 2.65 2071.60 5.184
19 17939 100277 3.53 2067.30 5.173
20 17954 118344 3.85 2063.89 5.165
21 17972 100038 3.52 2060.03 5.155
22 17998 92744 3.26 2055.17 5.145
23 18023 27438 0.97 2049.38 5.128
24 18158 258899 0.12 2020.17 5.055
25 18188 18883 0.38 2013.53 5.039
26 18218 10998 0.39 2006.85 5.022
27 18251 369086 0.13 2000.24 5.005
28 18366 231145 0.08 1868.43 4.675
29 18372 245785 0.09 1867.15 4.672
30 18379 248533 0.08 1865.65 4.668
31 18921 387787 0.14 1856.65 4.646
32 18947 491752 0.17 1851.87 4.632
142.99
31.29
221.63
10000.00
199.50
56.78
292.93
53.44
65.16
65.91
6.0
5.5
5.0
4.5
PPM

FIG. 3B



Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HI PPM
1 19726 426331 0.15 1469.81 3.678
2 19748 527978 0.19 1466.80 3.670
3 20791 284031K 99.98 1455.87 3.643
4 18865 445693 0.16 1440.82 3.603
5 12127 626774 0.22 1383.86 3.463
6 21158 555934 0.19 1377.22 3.446
7 24363 704264 0.25 690.34 1.727
8 24396 678389 0.24 683.26 1.710
9 24435 46718K 1.64 674.91 1.689
10 24466 4792K 1.69 668.26 1.672
11 24491 473535 0.17 662.98 1.659
12 24528 783577 0.28 654.97 1.639
13 24614 20840K 7.34 636.54 1.593
14 24619 21843K 7.69 635.47 1.590
15 24648 25726K 9.05 630.97 1.579
16 24647 28678K 10.09 629.47 1.575
17 24654 31520K 11.10 627.97 1.571
18 24665 47785K 16.82 625.61 1.566
19 24698 40218K 14.16 618.54 1.548
20 24708 37146K 13.08 617.04 1.544
21 24738 8542K 3.01 609.97 1.526
22 24788 1063K 0.37 599.25 1.500
23 24883 784986 0.28 596.04 1.491
24 24820 655835 0.23 592.39 1.482
25 24835 578158 0.20 589.18 1.474
26 24851 635737 0.22 585.75 1.466
27 24883 612780 0.22 578.89 1.449
28 24974 439638 0.15 559.39 1.400
17926.65
107.90
227.50
76.77
159.54
90.30
2643.75
478.12
69.83
41.57
4.0
3.5
3.0
2.5
2.0
1.5
1.0
PPM

FIG. 3C



Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 17783 519382 0.15 2180.54 5.456
2 17796 2872K 0.58 2837.75 5.249
3 17807 3417K 0.40 2835.39 5.243
4 17828 7280K 2.82 2890.89 5.232
5 17861 8695K 2.44 2883.82 5.214
6 17885 8139K 2.28 2878.03 5.200
7 17921 10316K 2.89 2870.96 5.182
8 17942 13709K 3.84 2866.46 5.171
9 17957 15146K 4.14 2863.25 5.163
10 17974 13705K 3.84 2859.68 5.154
11 17993 12782K 3.56 2855.53 5.144
12 18025 3777K 1.06 2848.46 5.126
13 18188 1213K 0.34 2813.74 5.059
14 18219 3232K 0.35 2807.18 5.022
15 18324 819895 0.15 1856.88 4.644
16 18350 666824 0.19 1850.43 4.638
135.88
28.58
783.67
0000.00
190.56
57.93
285.65
52.63
67.91
55.03
6.0
5.5
5.0
4.5
PPM

FIG. 3D



Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 28720 603304 0.17 1471.89 3.681
2 28745 984099 0.28 1465.73 3.668
3 28794 356908K 99.99 1455.23 3.641
4 23129 835651 0.23 1383.44 3.462
5 21151 734985 0.21 1376.58 3.445
6 24356 872582 0.24 689.69 1.726
7 24399 845968 0.24 682.62 1.708
8 24439 5427K 1.52 674.85 1.687
9 24471 5346K 1.50 667.19 1.670
10 24538 725303 0.20 654.55 1.638
11 24617 28815K 8.10 635.99 1.591
12 24622 30877K 8.43 634.83 1.589
13 24643 36184K 10.11 630.33 1.577
14 24658 39651K 11.11 628.83 1.574
15 24686 43547K 12.20 627.54 1.570
16 24668 67844K 18.78 624.97 1.564
17 24708 56296K 15.77 618.11 1.547
18 24708 58552K 14.16 616.48 1.542
19 24741 18761K 3.81 609.33 1.525
20 24791 1493K 0.42 598.61 1.498
21 24805 1141K 0.32 595.61 1.490
22 24823 955978 0.28 593.75 1.481
23 24838 854854 0.24 588.54 1.473
24 24854 939682 0.26 585.11 1.464
25 24886 8832398 0.25 578.25 1.447
26 24977 6411481 0.18 558.75 1.398
1757.01
121.56
255.90
89.47
146.77
72.35
3456.41
528.24
93.20
37.61
3.5
3.0
2.5
2.0
1.5
1.0
PPM

FIG. 3E




Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 16589 3765982 0.89 2357.25 5.899
2 17598 3526760 0.88 2141.82 5.358
3 17685 3988855 0.10 2139.52 5.354
4 17729 3884831 0.89 2132.94 5.287
5 17734 3726678 0.89 2131.87 5.285
6 17768 5826141 0.14 2106.38 5.271
7 17766 5736431 0.14 2105.81 5.267
8 17771 4684405 0.11 2103.94 5.265
9 17777 5110899 0.12 2102.66 5.262
10 17784 5397521 0.13 2101.16 5.258
11 17797 20031K 0.48 2098.37 5.251
12 17808 15088K 0.36 2096.01 5.245
13 17829 6869K 1.64 2091.51 5.234
14 17862 83166K 1.99 2084.44 5.216
15 17889 82088K 1.98 2078.65 5.202
16 17921 108529K 2.59 2071.79 5.184
17 17942 142466K 3.43 2067.29 5.173
18 17957 158644K 3.79 2064.08 5.165
19 17975 143088K 3.42 2060.22 5.155
20 17993 131758K 3.15 2056.36 5.146
21 18026 38587K 0.93 2049.29 5.128
22 18156 4208015 0.10 2021.43 5.058
23 18188 12655K 0.30 2014.57 5.041
24 18219 12988K 0.31 2007.93 5.025
25 18258 4438451 0.11 2001.28 5.008
26 18269 3568036 0.85 1998.62 4.676
27 18575 3983296 0.89 1867.34 4.673
28 18582 3748874 0.89 1865.84 4.669
29 18935 6024731 0.14 1856.62 4.646
30 18944 6344931 0.15 1852.55 4.636
31 18958 7759331 0.19 1851.26 4.633
155.51
35.49
395.60
6000.00
180.82
41.10
62.95
277.83
65.35
72.20
80.02
6.0
5.5
5.0
4.5
PPM

FIG. 3F


Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 20733 709831 0.17 1469.14 3.676
2 20746 558099 0.21 1466.35 3.669
3 20795 4185121K 99.99 1455.85 3.643
4 21138 938639 0.22 1384.95 3.463
5 21161 816841 0.20 1377.41 3.447
6 24367 955615 0.23 698.31 1.727
7 24480 951634 0.23 683.24 1.710
8 24441 5814K 1.39 674.45 1.688
9 24472 59352K 1.42 667.81 1.671
10 24493 756499 0.18 663.31 1.660
11 24529 779774 0.19 655.59 1.641
12 24638 298477K 7.13 636.52 1.593
13 24623 314123K 7.50 635.45 1.590
14 24644 364255K 8.70 630.95 1.579
15 24651 432263K 9.86 629.45 1.575
16 24657 456099K 10.90 628.16 1.572
17 24669 674923K 16.12 625.59 1.565
18 24701 568533K 13.58 618.73 1.548
19 24709 534455K 12.77 617.02 1.544
20 24741 126598K 3.02 610.16 1.527
21 24780 13382K 0.32 601.80 1.506
22 24792 15222K 0.36 599.23 1.499
23 24806 11228K 0.27 596.23 1.492
24 24825 9470936 0.23 592.16 1.482
25 24839 8496662 0.20 589.16 1.474
26 24855 9708080 0.23 585.73 1.466
27 24887 9512728 0.23 578.87 1.449
30269.54
16595.42
136.26
117.38
125.63
86.09
167.07
95.05
463.97
467.57
57.72
36.02
3.5
3.0
2.5
2.0
1.5
1.0
PPM

GPC Results

	SampleName	Mn	Mw	MP	Mz	Mz+1	Poly dispersity	Area (µV*sec)
1	11-187-1	17932	31382	28944	54646	92865	1.750072	125487
2	11-188-1	17452	29711	28240	48234	73135	1.702407	174329
3	11-198-1	17045	29148	26443	48733	77936	1.710106	107828




FIG. 4

FIG. 5A



Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 13516 311569 0.87 3816.87 7.547
2 13536 326720 0.88 3811.79 7.537
3 13543 362130 0.88 3810.29 7.533
4 13550 368845 0.88 3808.79 7.529
5 13558 383738 0.12 3807.87 7.525
6 13790 369953 0.89 3857.35 7.488
7 13833 358460 0.86 3948.13 7.377
8 13872 335548 0.88 3939.78 7.356
9 14042 357044 8.35 3903.34 7.265
10 14140 4336525 0.10 3882.34 7.213
11 14171 581269 0.14 3875.70 7.196
12 17798 22931 0.54 3898.37 5.251
13 17830 86521 2.82 3891.51 5.234
14 17863 184685 2.45 3884.44 5.216
15 17890 181022 2.36 3878.65 5.202
16 17923 128674 3.01 3871.58 5.184
17 17943 169934 3.97 3867.29 5.173
18 17958 189855 4.44 3864.08 5.165
19 17976 170955 4.80 3860.22 5.155
20 17994 160834 3.76 3856.36 5.146
21 18027 47955 1.12 3849.29 5.128
22 19453 3508076 0.88 1743.68 4.363
23 19486 3338857 0.88 1736.60 4.346
7.5
7.0
6.5
6.0
5.5
5.0
4.5
PPM

FIG. 5B




Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 26469 887535 0.19 1525.93 3.838
2 26493 918579 0.21 1520.79 3.886
3 26782 749245 0.18 1476.00 3.693
4 26724 918788 0.21 1471.25 3.682
5 26738 783591 0.18 1468.29 3.674
6 26795 4276798 100.00 1456.06 3.644
7 21130 825864 0.19 1384.27 3.464
8 24619 352155 8.23 636.52 1.593
9 24624 375638 8.78 635.45 1.590
10 24645 431144 10.08 638.95 1.599
11 24652 487338 11.40 629.45 1.575
12 24658 538788 12.60 628.16 1.572
13 24669 817422 19.11 625.80 1.566
14 14782 689258 16.12 618.73 1.548
15 24730 693838 14.94 617.02 1.544
16 24742 144428 3.38 610.16 1.527
17 24792 169118 0.40 599.44 1.500
18 24807 152568 0.36 596.23 1.492
19 24825 13728 0.32 592.37 1.482
20 24848 12778 0.30 589.16 1.474
21 24855 14168 0.33 585.94 1.466
22 24888 12378 0.29 578.87 1.449
1797.32
35534.59
166.60
352.79
54.17
106.76
54.60
128.01
145.61
67.20
74.60
3.5
3.0
2.5
2.0
1.5
1.0
PPM

FIG. 5C


Non-Interpolated Peak Listing
PEAK #POINT HEIGHT REL. HT HZ PPM
1 13544 413927 0.69 3009.88 7.532
2 13551 416896 0.69 3008.38 7.528
3 13558 542515 0.12 3006.88 7.524
4 13793 437833 0.10 2956.52 7.398
5 13828 434493 0.09 2950.73 7.384
6 14042 342867K 7.58 2903.15 7.265
7 14142 581426 0.11 2881.72 7.211
8 14171 663548 0.15 2875.58 7.196
9 17799 27528K 0.61 2897.97 5.259
10 17831 18341K 2.29 2891.11 5.233
11 17864 12477K 2.76 2884.84 5.215
12 17891 11573K 2.56 2878.25 5.200
13 17934 14387K 3.19 2871.18 5.183
14 17945 19073K 4.22 2866.88 5.172
15 17968 21328K 4.72 2863.46 5.163
16 17977 19241K 4.26 2859.82 5.154
17 17996 18213K 4.03 2855.75 5.144
18 18029 5453K 1.21 2848.67 5.126
164.63
316.62
238.45
3.08
3.02
35.76
100.00
109.26
77.25
99.49
94.55
7.5
7.0
6.5
6.0
5.5
5.0
4.5
PPM



Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 20471 978329 0.22 1525.31 3.817
2 20478 832908 0.18 1523.81 3.813
3 20495 80188 0.13 1520.17 3.804
4 20720 954383 0.21 1470.23 3.679
5 20744 953588 0.21 1466.80 3.670
6 20748 948790 0.21 1465.95 3.668
7 20796 4514838 100.00 1455.66 3.643
8 21131 965892 0.21 1383.86 3.463
9 24520 408368 8.87 636.11 1.592
10 24625 412908 9.37 635.84 1.589
11 24646 503858 11.16 630.54 1.578
12 24653 545368 12.15 629.04 1.574
13 24659 603668 13.37 627.76 1.571
14 24671 944848 20.93 625.18 1.564
15 24783 794688 17.68 618.33 1.547
16 24711 712228 15.77 616.61 1.543
17 24744 148818 3.28 609.54 1.525
18 24794 28438 0.45 598.82 1.498
19 24889 17958 0.40 595.61 1.490
20 24827 168838 0.35 591.75 1.481
21 24841 146778 0.32 588.75 1.473
22 24857 157238 0.35 585.32 1.465
23 24889 136898 0.30 578.46 1.448
7436.75
20629.72
108.37
335.11
59.37
103.59
49.99
122.78
33.11
178.17
66.62
81.22
3.5
3.0
2.5
2.0
1.5
1.0
PPM

FIG. 5D



NUMBER FROM TO VALUE
2 5.45 PPM 5.32 PPM 58.15
3 5.31 PPM 5.29 PPM 108.93
4 5.27 PPM 5.09 PPM 10000.00
5 5.08 PPM 5.00 PPM 88.44
6 5.00 PPM 4.92 PPM 56.28
7 4.75 PPM 4.50 PPM 75.93
8 4.45 PPM 4.31 PPM 101.46
9 4.30 PPM 4.17 PPM 97.57
6.0
5.5
5.0
4.5
PPM

FIG. 5E

FIG. 5F



Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 20447 512793 0.34 1538.24 3.829
2 20469 869231 0.24 1525.53 3.817
3 20475 753832 0.31 1524.24 3.814
4 20493 990869 0.25 1520.38 3.805
5 20700 484413 0.14 1476.82 3.694
6 20723 620768 0.17 1471.09 3.681
7 20731 640162 0.18 1469.38 3.677
8 20747 868155 0.24 1465.95 3.668
9 20795 354802K 99.99 1455.66 3.643
10 20865 627949 0.18 1436.37 3.594
11 20894 540083 0.15 1434.44 3.589
12 20912 527688 0.15 1430.59 3.580
13 21105 595815 0.17 1389.22 3.476
14 21130 749482 0.21 1383.86 3.463
15 21151 683343 0.17 1379.36 3.452
16 24623 39916K 8.71 635.26 1.590
17 24658 45185K 12.73 627.76 1.571
18 24669 66800K 18.83 625.48 1.565
19 24702 55722K 15.70 618.33 1.547
20 24709 53165K 14.98 616.83 1.544
21 24742 18526K 3.53 609.75 1.526
22 24792 1456K 0.42 599.04 1.499
23 24807 1385K 0.37 595.82 1.491
24 24826 1122K 0.32 591.75 1.481
25 24839 1067K 0.28 588.97 1.474
26 24855 1123K 0.32 585.54 1.465
27 24887 996375 0.28 578.68 1.448
28 24978 517884 0.15 559.18 1.399
19046.82
616.11
100.74
142.12
72.77
167.38
30670.91
363.19
511.82
112.26
66.75
63.75
3.5
3.0
2.5
2.0
1.5
1.0
PPM

FIG. 6A




Non-Interpolated Peak Listing
PEAK POINT HEIGHT REL. HT HZ PPM
1 17703 3287K 0.93 2118.33 5.301
2 17794 763233 0.59 2098.82 5.252
3 17827 2867K 2.22 2091.75 5.234
4 17859 3462K 2.68 2084.89 5.217
5 17886 3383K 2.55 2079.11 5.203
6 17919 4209K 3.26 2072.03 5.185
7 17940 5627K 4.35 2067.53 5.174
8 17955 6157K 4.76 2064.32 5.166
9 17973 5525K 4.27 2060.46 5.156
10 17991 5112K 3.95 2056.60 5.146
11 18024 1456K 1.35 2049.53 5.129
12 18084 38914 0.03 2036.67 5.096
13 18648 37951 0.03 1935.80 4.794
14 18668 48623 0.03 1913.23 4.788
15 18693 44943 0.03 1906.15 4.770
16 19434 43373 0.03 1751.63 4.383
17 19449 70126 0.05 1744.13 4.364
18 19482 68246 0.05 1737.06 4.347
19 19632 49538 0.04 1704.91 4.266
20 19640 50185 0.04 1703.20 4.262
21 19663 50170 0.04 1698.27 4.250
1000.00
20.76
26.12
41.62
37.38
24.32
66.08
67.37
5.45
54.05
55.49
PPM
6.0
5.5
5.0
4.5

FIG. 6B


NUMBER FROM TO VALUE
15 3.89 PPM 3.78 PPM 121.78
16 3.76 PPM 3.54 PPM 17119.73
17 3.53 PPM 3.41 PPM 2489.54
18 3.38 PPM 3.37 PPM 53.35
19 3.22 PPM 3.09 PPM 47.19
20 2.84 PPM 2.71 PPM 76.92
21 2.67 PPM 2.54 PPM 111.79
22 2.45 PPM 2.33 PPM 81.87
23 2.23 PPM 2.13 PPM 126.66
24 2.09 PPM 1.95 PPM 105.43
25 1.82 PPM 1.36 PPM 31348.29
26 1.34 PPM 1.23 PPM 2886.51
27 1.23 PPM 1.15 PPM 3432.05
28 1.09 PPM 1.03 PPM 45.01
29 0.96 PPM 0.78 PPM 1547.22
30 0.75 PPM 0.68 PPM 8.58
31 0.12 PPM 0.04 PPM 6.79
121.78
17120.73
2489.54
53.35
47.19
76.92
111.79
81.87
126.66
105.43
31346.29
2886.51
3432.05
45.01
1547.22
8.58
6.79
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
PPM

Sample	Sample description	Polymer	Polymer	Inherent Viscosity		Average	Standard
Code/Lot		solvent in	Conc.	Trial 1	Trial 2	IV	Deviation
		IV analysis	g/dL	dL/g	dL/g	dL/g	
11-196-6	PLA-PEG-lys-urea-glu(protected)	DMSO	0.1	0.229	0.205	0.217	0.016
44-49-1	PLA-PEG-lys-urea-glu	DMSO	0.1	0.198	0.198	0.198	0
44-49-1	PLA-PEG-lys-urea-glu	Chloroform	0.1	0.303	0.314	0.309	0.008

FIG. 7

SAMPLE ID	LAB ID	ANALYSIS	RESULT(S)		DUPLICATE RESULT(S)	
11-204-1	G-8391	Palladium	3780	ppm	3880	ppm
11-204-2	G-8392	Palladium	3.8	ppm	2.7	ppm

FIG. 8

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- **ZAUNER et al.** *Adv. Drug Del. Rev.,* 1998, vol. 30, 97 **[0019]**
- **KABANOV et al.** *Bioconjugate Chem.,* 1995, vol. 6, 7 **[0019]**
- **BOUSSIF et al.** *Proc. Natl. Acad. Sci., USA,* 1995, vol. 92, 7297 **[0019]**
- **KUKOWSKA-LATALLO et al.** *Proc. Natl. Acad. Sci., USA,* 1996, vol. 93, 4897 **[0019]**
- **TANG et al.** *Bioconjugate Chem.,* 1996, vol. 7, 703 **[0019]**
- **HAENSLER et al.** *Bioconjugate Chem.,* 1993, vol. 4, 372 **[0019]**
- **PUTNAM et al.** *Macromolecules,* 1999, vol. 32, 3658 **[0020]**
- **BARRERA et al.** *J. Am. Chem. Soc.,* 1993, vol. 115, 11010 **[0020]**
- **URN et al.** *J. Am. Chem. Soc.,* 1999, vol. 121, 5633 **[0020]**
- **ZHOU et al.** *Macromolecules,* 1990, vol. 23, 3399 **[0020]**
- **LIM et al.** *J. Am. Chem. Soc.,* 1999, vol. 121, 5633 **[0020]**
- **LIM.** *J. Am. Chem. Soc.,* 1999, vol. 121, 5633 **[0020]**
- Remington's Pharmaceutical Sciences. Mack Publishing Company, 1985 **[0063]**

Szabadalmi igénypontok

1. Eljárás nanorészecske előállítására, amely tartalmazza a következőket:

targetáló anyag (targeting agent) (TA) biztosítása;

a targetáló anyag funkciós csoportjainak védése;

funkcionalizált poli(etilén-glikol) (PEG) polimer biztosítása;

a funkcionalizált poli(etilén-glikol) polimer reagáltatása a védett targetáló anyaggal (PRO-TA) targetáló anyag-PEG polimer komplex képzésére;

a targetáló anyag-PEG polimer komplex konjugálása egy második polimerrel, targetáló anyag-PEG polimer-második polimer komplex képzésére; és

a targetáló anyag-PEG polimer-második polimer komplex összekeverése egy második polimerrel és egy gyógyszerészeti szerrel nanorészecske képzésére.

2. Az 1. igénypont szerinti eljárás, ahol a poli(etilén-glikol) hetero-bifunkcionális és a targetáló anyag kovalensen kapcsolódik a poli(etilén-glikol) α terminálisához és legalább egy polimerizációt iniciáló funkciós csoport jelen van a poli(etilén-glikol) ω terminálisán.

3. A 2. igénypont szerinti eljárás, ahol a szabad ω terminálison lévő legalább egy polimerizációt iniciáló funkciós csoport hidroxilcsoport (-OH) vagy aminocsoport ($-NH_2$), amely reagál a második kopolimerrel.

4. A 3. igénypont szerinti eljárás, ahol a második polimer tartalmazza két vagy több polimer keverékét és tartalmaz legalább egy funkciós csoportot, amely reagál a poli(etilén-glikol) szabad ω terminálisán jelen lévő funkciós csoporttal és a két vagy több polimer keverékében a legalább egy funkciós csoport hidroxilcsoport, NHS-csoport vagy aminocsoport.

5. Az 1. igénypont szerinti eljárás, ahol a második polimer vagy a kopolimer poliészter kopolimer, amely tartalmaz legalább egy, hidroxilcsoport, NHS-csoport vagy aminocsoport közül választott funkciós csoportot, és amely reagál a poli(etilén-glikol) szabad ω terminálisán jelen lévő funkciós csoporttal.

6. A 4. igénypont szerinti eljárás, ahol a második polimer vagy a kopolimer poliészter kopolimer, amely tartalmaz legalább egy, hidroxilcsoport, NHS-csoport vagy aminocsoport közül választott funkciós csoportot, és amely reagál a poli(etilén-glikol) szabad ω terminálisán lévő funkciós csoporttal.

7. A 6. igénypont szerinti eljárás, ahol a poliészter kopolimer tartalmaz heteropolimert vagy homopolimert.

8. A 7. igénypont szerinti eljárás, ahol a heteropolimer tartalmaz tejsav és glikolsav egységeket vagy poli(tejsav-ko-glikolsav) és poli(laktid-ko-glikolid) egységeket (PLGA); és a homopolimer tartalmaz glikolsav egységeket (PGA), tejsav egységeket (PLA), poli-L-tejsav egységeket, poli-D-tejsav egységeket, poli-D,L-tejsav egységeket, poli-L-laktid egységeket, poli-D-laktid egységeket vagy poli-D,L-laktid egységeket.

9. A 6. igénypont szerinti eljárás, ahol a poliészter kopolimer a következők közül választott: polihidroxisavak; laktid egységek és glikolid egységek pegilezett polimerei és kopolimerei, pegilezett PLA, pegilezett PGA, pegilezett PLGA, polianhidridek, poli(ortoészter), pegilezett poli(ortoészter), polikaprolakton, pegilezett polikaprolakton, polilizin, pegilezett polilizin, poli(etilén-inlin), pegilezett poli(etilén-imin), poli(L-laktid-ko-L-lizin), poli(szerinészter), poli(4-hidroxi-L-prolin-észter), poli[a-(4-aminobutil)-L-glikolsav] vagy ezek származékai.

SZTNH-100088672

10. Az 1. igénypont szerinti eljárás, ahol a targetáló anyagon lévő funkciós csoport szabad karbonsav-csoport vagy szabad hidroxilcsoport és a szabad karbonsav-csoportot vagy a szabad hidroxilcsoportot védjük mielőtt a funkcionalizált poli(etilén-glikol) polimert a targetáló anyaggal reagáltatjuk targetáló anyag-PEG polimer komplex képzésére.

11. A 4. igénypont szerinti eljárás, ahol a második polimer funkciós csoportja a következő:

a) aminocsoport, amely reagál a targetáló anyag-PEG komplexen lévő hidroxilcsoporttal vagy karbonsav-csoporttal; vagy

b) hidroxilcsoport vagy NHS-csoport, amely reagál a targetáló anyag-PEG komplexen lévő aminocsoporttal.

12. A 6. igénypont szerinti eljárás, ahol a második polimer vagy kopolimer funkciós csoportja a következő:

a) aminocsoport, amely reagál a targetáló anyag-PEG komplexen lévő hidroxilcsoporttal vagy karbonsav-csoporttal; vagy

b) NHS vagy hidroxilcsoport, amely reagál a targetáló anyag-PEG komplexen lévő aminocsoporttal.

13. Az 1. igénypont szerinti eljárás, ahol a második polimer legalább két polimer keveréke, amelyek azonos vagy eltérő polimerek lehetnek, ahol a legalább két polimerből az első tartalmaz funkciós csoportként legalább egy hidroxilcsoportot vagy NHS-csoportot és a legalább két polimerből a második tartalmaz funkciós csoportként legalább egy aminocsoportot.

14. Az 1. igénypont szerinti eljárás, ahol a gyógyszerészeti szer antibiotikum, rákellenes szer, vírusellenes szer, gyulladásgátló szer, diagnosztikai szer, oltóanyag antigén vagy gyógyhatású táplálék.

15. Az 1. igénypont szerinti eljárás, ahol a legalább egy targetáló anyag a következők közük választott: antitestek, prosztata specifikus membrán antigén (PMSA) ligandumok, és polipeptidek, amelyek az epidermális növekedési faktor receptorhoz (EGFR), szomatosztatin receptorhoz (SSTR), inzulinszerű növekedési faktor receptorhoz, folsav receptorhoz, HER2 receptorhoz, interleukin-13 receptorhoz, gasztrin-felszabadító peptid receptorhoz, CD30-hoz, vazoaktív intesztinális peptid receptorhoz, gasztrin receptorhoz, prosztata-specifikus antigénhez és/vagy az ösztrogén receptorhoz kapcsolódnak.

16. Az 1. igénypont szerinti eljárás, ahol az eljárást vizes közegben vagy szerves oldószerben végezzük.